Top

Frank V. Fossella, MD

Department of Thoracic-Head & Neck Med Onc, Division of Cancer Medicine

About Dr. Frank V. Fossella

I am a clinician researcher who has been involved in patient care and research in the field of lung cancer since 1987. I have vast experience serving as the principal investigator for lung cancer clinical trials, having conducted and reported on studies that range from phase I to phase III. I have developed and participated in over 50 clinical studies and have reported these in various peer-reviewed journals.

Primary Appointment

Associate Medical Director, Department of Thoracic/Head and Neck Medical Oncology, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Professor of Medicine and Internist, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor of Medicine and Internist, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Clinical Interests

Treatment of Lung Cancer

Education & Training

Degree-Granting Education

1982	Baylor College of Medicine, Houston, Texas, US, MD
1978	Cornell University College of Arts and Sciences, Ithaca, New York, US, Biology, BA

Postgraduate Training

1985-1987	Medical Oncology Fellowship, Baylor College of Medicine Affiliated Hospitals, Houston, Texas
1982-1985	Internal Medicine Residency, Internal Medicine, Baylor College of Medicine Affiliated Hospitals, Houston, Texas

Licenses & Certifications

1987	Medical Oncology
1985	Internal Medicine
1982	Texas

Experience & Service

Faculty Academic Appointments

Associate Professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1994 - 2000

Medical Director, Department of Thoracic/Head and Neck Medical Oncology, Thoracic Oncology Multidisciplinary Care Center, Houston, TX, 1992 - 2020

Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1991 - 1994

Assistant Professor, Baylor College of Medicine, Houston, TX, 1989 - 1990

Assistant Internist and Instructor, Department of Thoracic/Head and Neck Medical Oncology - Research, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1987 - 1988

Administrative Appointments/Responsibilities

Associate Medical Director, Department of Thoracic/Head and Neck Medical Oncology, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2020 - Present

MDACC Sister Institution Peer to Peer consultant, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - Present

Deputy Chairman, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1998 - 2006

Other Professional Positions

Panel Member, Radiological Society of North America Oncodiagnosis, Houston, TX, 1998 - 1999

Member, National Comprehensive Cancer Network (NCCN), Houston, TX, 1995

Expert Panelist, Rhone-Poulenc Rorer, Houston, TX, 1994

Member, Radiation Therapy Oncology Group (RTOG), Houston, TX, 1990

Extramural Institutional Committee Activities

Committee member, In-Patient-to-Hospice Task Force Committee, The University of Texas MD Anderson Cancer Center, 2017

Member, Committee for updating lung cancer algorithms, The University of Texas MD Anderson Cancer Center, 2014

Member, Electronic Health Record Committee, The University of Texas MD Anderson Cancer Center, 2014

Member, Thoracic Ambulatory Content Specialty Committee, The University of Texas MD Anderson Cancer Center, 2014

Member, CSAC Thoracic Program Review, The University of Texas MD Anderson Cancer Center, 2008 - Present

Member, Clinical Effectiveness Subcommittee Thoracic Workgroup, The University of Texas MD Anderson Cancer Center, 2008 - Present

Member, CSAC Thoracic Program Review, The University of Texas MD Anderson Cancer Center, 2008 - Present

Member, Clinical Safety and Effectiveness Program Session 8, The University of Texas MD Anderson Cancer Center, 2007 - 2008

Member, University of Texas M.D. Anderson Cancer Center Physicians Network Lung Multidisciplinary Planning Conference, The University of Texas MD Anderson Cancer Center, 2007 - Present

Member, Clinical Effectiveness Subcommittee Thoracic Workgroup, The University of Texas MD Anderson Cancer Center, 2007 - Present

Member, Ad Hoc Committee for Maintenance of Care Pathways, The University of Texas MD Anderson Cancer Center, 2001

Consultant, M. D. Anderson-Espana, The University of Texas MD Anderson Cancer Center, 2001

Member, Care Coordination Redesign Project Committee, The University of Texas MD Anderson Cancer Center, 2001

Representative, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2000

Member, Diagnostic Imaging Users Group, The University of Texas MD Anderson Cancer Center, 1999

Member, Faculty Achievement Award Selection Committee, The University of Texas MD Anderson Cancer Center, 1998

Member, Document Management System Involved Provider Data Base Rules Committee, The University of Texas MD Anderson Cancer Center, 1998 - 1999

Member, Computer-based Patient Record Design and Implementation Team, The University of Texas MD Anderson Cancer Center, 1997

Member, Patient Care Council, The University of Texas MD Anderson Cancer Center, 1997 - 1998

Member, Cancer Manager Network Medical Management Committee, The University of Texas MD Anderson Cancer Center, 1997 - 1998

Member, Bed Allocation Working Group, The University of Texas MD Anderson Cancer Center, 1997 - 1998

Member, Palliative Care Advisory Group, The University of Texas MD Anderson Cancer Center, 1997 - 1998

Member, Second Opinion Program Committee, The University of Texas MD Anderson Cancer Center, 1997 - 1998

Member, Managed Care Operations Committee, The University of Texas MD Anderson Cancer Center, 1997 - 1999

Member, Quality Management Subcommittee, The University of Texas MD Anderson Cancer Center, 1997 - 1999

Member, Patient Billing Services Collection Committee, The University of Texas MD Anderson Cancer Center, 1997 - 1999

Member, Billing and Collections Procedures Forum, The University of Texas MD Anderson Cancer Center, 1997 - 1999

Member, Oncology Editorial Advisory Board, The University of Texas MD Anderson Cancer Center, 1997 - Present

Member, Cancer Manager Utilization Management Committee, The University of Texas MD Anderson Cancer Center, 1997

Member, Cancer Consultant Pilot Committee, The University of Texas MD Anderson Cancer Center, 1997

Member, Customer Service Initiative Task Group Project Team for Improving Follow-up Communication with Referring Physicians, The University of Texas MD Anderson Cancer Center, 1996 - 1997

Member, Managed Care Strategy Committee, The University of Texas MD Anderson Cancer Center, 1996 - 1997

Member, Records and Documentation Working Group, The University of Texas MD Anderson Cancer Center, 1996 - 1997

Member, Non-Acute/Alternate Level of Care Project Committee, The University of Texas MD Anderson Cancer Center, 1996 - 1997

Panelist, M. D. Anderson Faculty/Administrator Advisory Panel, The University of Texas MD Anderson Cancer Center, 1996 - 1997

Member, Professional Contribution and Performance Committee, The University of Texas MD Anderson Cancer Center, 1996 - 1998

Member, Gastrostomy Task Force Committee, The University of Texas MD Anderson Cancer Center, 1996 - 1998

Assistant Medical Director, Contract Utilization Management Office, The University of Texas MD Anderson Cancer Center, 1996

Member, Telemedicine Committee, The University of Texas MD Anderson Cancer Center, 1995

Participant, Faculty Development Course on the Clinical Encounter and the Physician-Patient Relationship, The University of Texas MD Anderson Cancer Center, 1995

Member, Practice Outcomes Program Steering Committee, The University of Texas MD Anderson Cancer Center, 1995

Member, Advanced Clinical Practitioner Working Group, The University of Texas MD Anderson Cancer Center, 1995 - 1996

Member, Institutional Direction Working Group Committee, The University of Texas MD Anderson Cancer Center, 1995 - 1996

Member, Second Opinion, Diagnosis, and Treatment Planning Implementation Working Group Committee, The University of Texas MD Anderson Cancer Center, 1995 - 1996

Participant, Leadership Development Program for Center Directors, The University of Texas MD Anderson Cancer Center, 1995 - 1996

Member, Development of Thoracic Oncology Second Opinion and Consultation Template, The University of Texas MD Anderson Cancer Center, 1995 - 1996

Member, OneCare Physician Panel, The University of Texas MD Anderson Cancer Center, 1995 - 1998

Member, Practice Guidelines Review Committee, The University of Texas MD Anderson Cancer Center, 1995 - 2000

Member, Development of Thoracic Oncology Practice Guidelines, The University of Texas MD Anderson Cancer Center, 1995

Member, Development of Thoracic Medical Oncology Critical Care Paths, The University of Texas MD Anderson Cancer Center, 1995

Member, Ethel Fleming Arceneaux Outstanding Nurse Oncologist Award Selection Committee, The University of Texas MD Anderson Cancer Center, 1994 - 1996

Member, Quality Improvement Committee, The University of Texas MD Anderson Cancer Center, 1994 - 1999

Departmental Liaison, Office of Managed Care, The University of Texas MD Anderson Cancer Center, 1994 - 2000

Member, Faculty Productivity Working Group, The University of Texas MD Anderson Cancer Center, 1993 - 1994

Member, Pharmacy & Therapeutics Committee, The University of Texas MD Anderson Cancer Center, 1993 - 1994

Member, Quality Improvement Committee, The University of Texas MD Anderson Cancer Center, 1992 - 1994

Member, Quality Assurance Committee, The University of Texas MD Anderson Cancer Center, 1988

Honors & Awards

2020	Melvin L. Samuels Award: Excellence in Patient Care, MD Anderson Cancer Center
2007 - 2024	Leading Health Professionals in the World
2006 - 2024	Houston Top Doctor, Houston Magazine
2005 - 2007	Apple Award for Health Care Education
2004 - 2007	Texas Super Doctor, Texas Monthly Publications
2003 - 2024	Best Doctors in America
2001 - 2024	"America's Top Doctors", Castle Connolly
2000	Good Housekeeping Recognition as one of the “Best Doctors for Breast, Lung, and Colorectal Cancer”
1999	Julie and Ben Rogers Award for Excellence in Patient Care
1996	Faculty Achievement Award for Patient Care
1986	American Cancer Society Fellowship Award, Baylor College of Medicine
1982	Excellence in Physiology Award, Baylor College of Medicine
1982	Marrs McLean Award for Excellence in Biochemistry, Baylor College of Medicine
1978	B.A. with Distinction in All Subjects, Cornell University
1974 - 1978	Cornell University Dean's List

Professional Memberships

American Society of Clinical Oncology

1982 - Present

International Association for the Study of Lung Cancer

1982 - Present

Texas Medical Association

1982 - Present

American Medical Association

1982 - Present

Harris County Medical Society

1982 - Present

American Association for Cancer Research

1981 - Present

American College of Physicians

1980 - Present

Selected Presentations & Talks

Local Presentations

1997. Multimodality Treatment of Locally Advanced Non-Small Cell Lung Cancer. Conference. M. D. Anderson Advances in Oncology Institutional Grand Rounds. Houston, TX, US.
1997. Gemcitabine for Non-small Cell Lung Cancer. Invited. Texas Oncology, PA Tumor Board Conference. Houston, TX, US.
1996. Multimodality Treatment of Stage III Non-small Cell Lung Cancer. Conference. M. D. Anderson Cancer Center. Houston, TX, US.
1991. Interim Report of a Prospective Randomized Trial of Neoadjuvant Chemotherapy Plus Surgery vs Surgery Alone for IIIa Non-small Cell Lung Cancer. Invited. Interim Report of a Prospective Randomized Trial of Neoadjuvant Chemotherapy Plus Surgery vs Surgery Alone for IIIa Non-small Cell Lung Cancer. Houston, TX, US.

Regional Presentations

1999. Second-Line Chemotherapy for Stage IV Non-Small Cell Lung Cancer. Conference. Fourth Annual Perspectives in Thoracic Cancer. Dallas, TX, US.
1998. Multimodality Treatment of Locally Advanced Non-Small Cell Lung Cancer. Conference. M. D. Anderson Outreach. Abilene, TX, US.
1997. Docetaxel for Non-small Cell Lung Cancer. Conference. SWOG. Austin, TX, US.
1997. Phase I Study of Taxol, Cisplatin, and Etoposide with G-CSF in Patients with Non-small Cell Lung Cancer. Invited. Phase I Study of Taxol, Cisplatin, and Etoposide with G-CSF in Patients with Non-small Cell Lung Cancer. Dallas, TX, US.
1997. Gemcitabine for Non-Small Cell Lung Cancer. Conference. Texas Oncology, PA Tumor Board Conference. Dallas, TX, US.
1996. Gemcitabine for Treatment of Advanced Pancreatic and Non-small Cell Lung Cancer. Conference. Texas Tech University Health Sciences Center Oncology Grand Rounds. Lubbock, TX, US.
1994. Taxotere (Docetaxel), an Active Agent for Platinum-Refractory Non-small Cell Lung Cancer: Preliminary Report of a Phase II Study. Invited. Taxotere (Docetaxel), an Active Agent for Platinum-Refractory Non-small Cell Lung Cancer: Preliminary Report of a Phase II Study. Dallas, TX, US.
1994. Taxotere (Docetaxel), an Active Agent for Recurrent/Metastatic Non-small Cell Lung Cancer: Preliminary Report of a Phase II Study. Invited. Taxotere (Docetaxel), an Active Agent for Recurrent/Metastatic Non-small Cell Lung Cancer: Preliminary Report of a Phase II Study. Dallas, TX, US.

National Presentations

2000. Roswell Park Community Cancer Network Lung Cancer Consensus Conference. Invited. Roswell Park Community Cancer Network Lung Cancer Consensus Conference. Buffalo, NY, US.
1999. Diagnosis and Multidisciplinary Approach for Lung Cancer. Invited. Oncodiagnosis Panel – Radiological Society of North America Annual Meeting Refresher Course. Chicago, IL, US.
1999. Docetaxel for Treatment of Non-Small Cell Lung Cancer. Invited. Nonplatinum-Based Chemotherapy in the Treatment of Non-Small Cell Lung Cancer. Philadelphia, PA, US.
1999. Multimodality Treatment of Locally Advanced Non-Small Cell Lung Cancer. Invited. M. D. Anderson Cancer Center Orlando. Orlando, FL, US.
1999. Gemcitabine Plus Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer. Invited. Radiation Therapy Oncology Group Semi-Annual Meeting. Atlanta, GA, US.
1998. Management of Lung Cancer: Case Presentations. Invited. Radiological Society of North America Refresher Course. Chicago, IL, US.
1998. Multimodality Treatment of Locally Advanced Non-Small Cell Lung Cancer. Invited. St. Vincent’s Medical Center Grand Rounds. Staten Island, NY, US.
1997. Advances in the Treatment of Non-small Cell Lung Cancer. Invited. St. Francis Memorial Hospital Noon Conference. San Francisco, CA, US.
1997. Maximum Tolerated Dose for Single-agent Gemcitabine: A Phase I Dose Escalation Study in Chemotherapy-Naive Patients with Advanced Non-small Cell Lung Cancer. Invited. Gemzar U.S. Investigators Meeting. Washington, US.
1997. Single-agent Taxotere in Refractory Patients with Non-small Cell Lung Cancer. Invited. Non-small Cell Lung Cancer Roundtable. Naples, FL, US.
1996. Second Line Chemotherapy in Non-small Cell Lung Cancer. Invited. Perspectives in Lung Cancer. Atlanta, GA, US.
1996. Gemcitabine for Treatment of Advanced Pancreatic and Non-small Cell Lung Cancer. Invited. St. Joseph Regional Cancer Center Tumor Board Conference. Albuquerque, NM, US.
1995. Gemzar Phase I Short Infusion. Conference. Eli Lilly. Indianapolis, IN, US.
1994. M. D. Anderson Experience with Taxotere for Non-small Cell Lung Cancer. Conference. American Chemical Associate. Washington, US.
1993. Phase II Study of Cisplatin Plus Carboplatin for Extensive Small Cell Lung Cancer. Conference. Phase II Study of Cisplatin Plus Carboplatin for Extensive Small Cell Lung Cancer. Orlando, FL, US.

International Presentations

2001. Gemcitabine with concurrent chest radiation followed by consolidation chemotherapy with gemcitabine plus cisplatin: a phase I trial for patients with stage III non-small cell lung cancer. Conference. European Congress of Clinical Oncology Meeting. Lisbon, PT.
2001. Docetaxel + cisplatin and docetaxel + carboplatin vs vinorelbine + cisplatin in chemotherapy-naïve patients with advanced and metastatic non-small cell lung cancer. Conference. European Congress of Clinical Oncology Meeting. Lisbon, PT.
2001. Targeted Therapy for the Treatment of Non-small Cell Lung Cancer. Invited. New Approaches in the Treatment of Non-Small Cell Lung Cancer. Rome, IT.
2001. Second-Line Chemotherapy for Non-Small Cell Lung Cancer: Establishing a Gold Standard. Invited. New Approaches in the Treatment of Non-Small Cell Lung Cancer. Rome, IT.
2001. A multicenter, randomized phase III study of docetaxel + cisplatin (DC) and docetaxel + carboplatin (DCB) vs. vinorelbine + cisplatin (VC) in chemotherapy-naïve patients with advanced and metastatic non-small cell lung cancer. Conference. ASCO. San Francisco, US.
2001. Gemcitabine (G) with concurrent chest radiation (XRT) followed by consolidation chemotherapy with gemcitabine plus cisplatin (CDDP): a phase I trial for patients with stage III non-small cell lung cancer (NSCLC). Conference. ASCO. San Francisco, US.
2000. Gemcitabine (G) with concurrent chest radiation (XRT) followed by consolidation chemotherapy with gemcitabine plus cisplatin (CDDP): a phase I trial for patients with stage III non-small cell lung cancer (NSCLC). Conference. 9th World Conference on Lung Cancer. Tokyo, JP.
1999. New Treatment Options After Standard Chemotherapy Has Failed in NSCLC. Invited. ASCO Fall Education Conference. San Francisco, US.
1999. Docetaxel Monotherapy: Data Review. Invited. First International Forum on Lung Cancer Treatment. Toronto, CA.
1999. New Treatment Options After Standard Chemotherapy Has Failed in NSCLC. Invited. European Conference of Clinical Oncology. Vienna, AT.
1999. Expanding Options in the Treatment of Non-Small Cell Lung Cancer. Invited. Current Perspectives in the Treatment of Advanced Cancer. Sydney, AU.
1999. Future Direction in the Treatment of Non-Small Cell Lung Cancer. Invited. Current Perspectives in the Treatment of Advanced Cancer. Sydney, AU.
1999. Phase I Trial of Concurrent Gemcitabine plus Chest Radiotherapy, Followed by Consolidation Systemic Chemotherapy with Gemcitabine plus Cisplatin, for Patients with Stage III and Medically Inoperable Stage II Non-Small Cell Lung Cancer. Conference. ASCO. Atlanta, US.
1999. Phase III Trial of Docetaxel 100 mg/m2 or 75 mg/m2 versus Vinorelbine/Ifosfamide for NSCLC Previously Treated with Platinum-Based Chemotherapy. Conference. ASCO. Atlanta, US.
1999. Advances in the Treatment of Lung Cancer. Invited. VII Congress of the Spanish Society of Medical Oncology. Sitges, ES.
1999. Docetaxel in the Second-Line Treatment of Non-Small Cell Lung Cancer. Invited. Ninth International Congress on Anti-Cancer Treatment. Paris, FR.
1998. Options After Failure of First-Line Platinum-Based Treatment for Non-small Cell Lung Cancer: Review of a Recently Completed Phase III Trial. Invited. European Society of Medical Oncology Symposium. Athens, GR.
1997. Docetaxel for Non-small Cell Lung Cancer. Invited. International Association for the Study of Lung Cancer 8th World Conference on Lung Cancer Symposium on Chemotherapy New Agents/Combinations for Non-small Cell Lung Cancer. Dublin, IE.
1997. New Drug Development for Non-Small Cell Lung Cancer. Invited. International Association for the Study of Lung Cancer 8th World Conference on Lung Cancer. Dublin, IE.
1997. Paclitaxel and Docetaxel in Non-small Cell Lung Cancer: The Experience of UT M. D. Anderson. Invited. National Tumor Institute of Naples Conference on New Trends in the Treatment of Lung Cancer. Naples, IT.
1997. The Combined Chemo-Radiotherapy Approach to Locally Advanced Non-Small Cell Lung Cancer: The Experience of UT M. D. Anderson. Invited. National Tumor Institute of Naples Conference on New Trends in the Treatment of Lung Cancer. Naples, IT.
1996. Phase I Trial of GL331, a Novel Topoisomerase-II Inhibitor, for Advanced Refractory Cancer. Conference. ASCO. Philadelphia, US.
1996. Phase I/II Study of Gemcitabine, an Active Agent for Advanced Non-small Cell Lung Cancer. Conference. Sixth International Congress on Anti-Cancer Treatments. Paris, FR.
1995. Phase I Trial of GL331, a Novel Topoisomerase-II Inhibitor, for Advanced refractory Cancer. Conference. European Conference on Clinical Oncology Meeting. Paris, FR.
1995. New Drug Development for Non-small Cell Lung Cancer. Invited. Sociedad Mexicana de Estudio Oncologicos National Meeting Educational Session. Monterrey, MX.
1995. Multimodality Treatment of Stage III Non-small Cell Lung Cancer. Invited. Sociedad Mexicana de Estudio Oncologicos National Meeting Educational Session. Monterrey, MX.
1994. Taxotere (Docetaxel) for Previously Untreated Advanced Non-Small Cell Lung Cancer: Combined Results of 3 Phase II Trials. Conference. European Society of Medical Oncology Meeting. Lisbon, PT.
1994. Taxotere (Docetaxel) for Platinum - Refractory Non-Small Cell Lung Cancer: Combined Results of 2 Phase II Trials. Conference. European Society of Medical Oncology Meeting. Lisbon, PT.
1994. Non-small Cell Lung Cancer Chemotherapy: New Agents. Conference. 7th World Congress in Lung Cancer. Colorado Springs, US.
1994. Taxotere (Docetaxel), An Active Agent for Non-Small Cell Lung Cancer: Preliminary Report of 2 Phase II Studies. Conference. 7th World Conference on Lung Cancer Meeting. Colorado Springs, US.
1994. Dosage and Dose Scheduling of Gemcitabine. Conference. 7th World Congress on Lung Cancer. Colorado Springs, US.
1994. M. D. Anderson Experience with Gemcitabine for Non-Small Cell Lung Cancer. Conference. ASCO. Chicago, US.
1993. Phase I Studies of Gemcitabine. Conference. European Conference on Clinical Oncology Meeting. Jerusalem, IL.
1993. Phase I/II Study of Gemcitabine by 30-minute Weekly Intravenous Infusion X 3 Weeks Every 4 Weeks for Non-small Cell Lung Cancer. Conference. ASCO. Orlando, US.
1992. Phase I/II Study of Multidose Samarium-153-EDTMP for Bone Metastases. Conference. Phase I/II Study of Multidose Samarium-153-EDTMP for Bone Metastases. Lyon, FR.
1992. Phase I Study of Multidose Samarium-153-EDTMP for Bone Metastases. Conference. ASCO. San Diego, US.
1991. Interim Report - Prospective Randomized Trial of Neoadjuvant Chemotherapy Plus Surgery vs Surgery Alone for IIIa Non-small Cell Lung Cancer. Conference. Interim Report - Prospective Randomized Trial of Neoadjuvant Chemotherapy Plus Surgery vs Surgery Alone for IIIa Non-small Cell Lung Cancer. Florence, IT.

Less

Grant & Contract Support

Date:	2008 - 2010
Title:	Protocol H3D-MC-JMHO, A Randomized Phase 3 Trial of ALIMTA (Pemetrexed) and Carboplatin vs Etoposide and Carboplatin in Extensive-State Small Cell Lung Cancer
Funding Source:	Eli Lilly
Role:	PI
ID:	2004-0297

Date:	2005 - 2011
Title:	A Phase I Study of Daily Dosing with BB-10901 in Patients with Small Cell Lung Cancer
Funding Source:	Vernalis Pharmaceuticals
Role:	PI

Date:	2005 - 2006
Title:	Multicenter Phase II Study of Velcade (Bortezomib) in Previously Treated Patients with Stable IIB and IV Bronchioloalveolar Carcinoma and Adenocarcinoma with BAC Features
Funding Source:	Millenium Pharmaceuticals
Role:	PI
ID:	CS2003-00008266DH 01

Date:	2004 - 2006
Title:	Phase II Timing Study of Technitium-Annexin V for Imaging of Apoptosis in Patients with NSCLC
Funding Source:	Theseus Imaging Corporation
Role:	PI

Date:	2002 - 2004
Title:	Phase 1 open-label, dose escalation study of daily dosing with BB-0191, (ID01-032) CS01-103
Funding Source:	Immunogen
Role:	PI
ID:	2004-0557

Date:	2002 - 2004
Title:	Randomized Multicenter Phase II Study of Velcade Alone or Velcade plus Docetaxel in Previously Treated Patients with Advanced NSCLC
Funding Source:	Millenium Pharmaceuticals
Role:	PI

Date:	2001 - 2006
Title:	Phase I open-label, dose escalation study of weekly dosing with BB-0191
Funding Source:	Immunogen
Role:	PI
ID:	(ID01-032) CS01-103

Date:	2001 - 2006
Title:	NO TITLE PROVIDED
Funding Source:	Aventis Pharmaceuticals Fellowship Educational Grant
Role:	PI

Date:	2000 - 2006
Title:	A Phase I, Open-Label Dose Escalation Study of Weekly Dosing with BB-10901 in Patients with Small Cell Lung Cancer, Followed by a Phase II Efficacy Expansion
Funding Source:	British Biotech Pharmaceuticals
Role:	PI

Date:	2000 - 2006
Title:	NO TITLE PROVIDED
Funding Source:	Lale Ersu Lung Cancer Research Fund
Role:	PI

Date:	2000 - 2003
Title:	Phase III Trial of ALIMTA vs Docetaxel in Patients with Locally Advanced Metastatic Non-Small Cell Lung Cancer who Were Previously Treated with Chemotherapy
Funding Source:	Eli Lilly Pharmaceuticals
Role:	PI

Date:	1999 - 2001
Title:	Phase II Study of RPR 109881 1-Hour IV Infusion Every 3 Weeks to NSCLC Patients with Brain Metastases
Funding Source:	Rhone-Poulenc Rorer
Role:	PI

Date:	1999
Title:	NO TITLE PROVIDED
Funding Source:	Kenneth Schnitzer Fund for Lung Cancer Research
Role:	PI

Date:	1999 - 2006
Title:	NO TITLE PROVIDED
Funding Source:	Saurine L. and Eugene D. Brown Lung Cancer Research Fund
Role:	PI

Date:	1998
Title:	NO TITLE PROVIDED
Funding Source:	Eugene Brown Memorial Fund
Role:	PI

Date:	1998
Title:	NO TITLE PROVIDED
Funding Source:	Karen Susman Memorial Fund
Role:	PI

Date:	1998
Title:	NO TITLE PROVIDED
Funding Source:	Joseph Bartolotta Memorial Fund
Role:	PI

Date:	1998 - 2001
Title:	A Multicenter, Multinational, Randomized Phase III Study of Docetaxel Plus Cisplatin versus Docetaxel Plus Carboplatin versus Vinorelbine Plus Cisplatin in Chemotherapy-Naïve Patients with Unresectable Locally Advanced and/or Recurrent or Metastatic (Stage IV) NSCLC
Funding Source:	Rhone-Poulenc Rorer
Role:	PI

Date:	1998 - 2001
Title:	Phase II Evaluation of Docetaxel plus Gemcitabine as First-Line and Second-Line Treatment for Patients with Stage IIIb and Stage IV NSCLC
Funding Source:	Rhone-Poulenc Rorer
Role:	PI

Date:	1998 - 2006
Title:	Erythropoietin +/- Iron Supplementation during Chemotherapy with Carboplatin and Paclitaxel
Funding Source:	Ortho-Biotech
Role:	PI

Date:	1998 - 2006
Title:	Procrit vs no Procrit on Clinical Outcomes of Chemotherapy-Naïve Patients Receiving Chemotherapy for h Advanced NSCLC
Funding Source:	Ortho-Biotech
Role:	PI

Date:	1997 - 2006
Title:	Phase I Evaluation of Concurrent Gemcitabine Plus Chest Radiotherapy, Followed by Consolidation Systemic Chemotherapy with Gemcitabine Plus Cisplatin, for Patients with Stage III and Inoperable Stage II NSCLC
Funding Source:	Eli Lilly and Company
Role:	PI

Date:	1997
Title:	NO TITLE PROVIDED
Funding Source:	Lloyd Ross Memorial Fund
Role:	PI

Date:	1997
Title:	NO TITLE PROVIDED
Funding Source:	Faculty Achievement Award for Patient Care
Role:	PI

Date:	1996 - 1997
Title:	Living With Lung Cancer Project
Funding Source:	University Cancer Foundation
Role:	PI

Date:	1995 - 1997
Title:	A Multicenter Randomized Phase III Study of Docetaxel (Taxotere) 100 mg/m² or 75 mg/m² versus Vinorelbine or Ifosfamide in Patients with Non-small Cell Lung Cancer Previously Treated with Platinum - Based Chemotherapy
Funding Source:	Rhone-Poulenc Rorer
Role:	PI

Date:	1995 - 1997
Title:	A Randomized Phase II Trial Comparing High and Low Dose Gemcitabine in a Short, Weekly Infusion Schedule In NSCLC
Funding Source:	Eli Lilly and Company
Role:	PI

Date:	1994 - 1996
Title:	Phase II Study of Dexniguldipine in Relapsed Small Cell Lung Cancer
Funding Source:	Byk-Gulden
Role:	PI

Date:	1994 - 1996
Title:	A Multi-Center Open-labeled Phase II Study to Evaluate Preliminary Efficacy of Intravenous ATP for the Treatment of Inoperable, Previously Untreated Stage IIIb-IV NSCLC
Funding Source:	Medco Research, Inc
Role:	PI

Date:	1994 - 1996
Title:	Phase II Study of CI958 in Patients with Advanced Lung Cancer
Funding Source:	Parke-Davis
Role:	PI

Date:	1993
Title:	Phase I Clinical Study of Lometrexol (LY264618)
Funding Source:	Eli Lilly and Company
Role:	PI

Date:	1993 - 1996
Title:	A Phase I Evaluation of GL331 in Patients with Advanced Cancer
Funding Source:	Genelabs, Inc
Role:	PI

Date:	1993 - 1995
Title:	Phase II Study of Brief Intravenous Adozelesin Infusion in Previously Untreated Extensive Small Cell Lung Cancer
Funding Source:	Upjohn, Inc
Role:	PI

Date:	1993
Title:	NO TITLE PROVIDED
Funding Source:	Betty Lyn Liedtke Memorial Fund for Lung Cancer Research
Role:	PI

Date:	1992
Title:	NO TITLE PROVIDED
Funding Source:	O. Pendleton Thomas Memorial Fund Research Grant
Role:	PI

Date:	1992 - 1995
Title:	Phase II Trial of RP 56976 (Taxotere) in Patients With Non-small Cell Lung Cancer Previously Treated With Platinum-Based Cytotoxic Chemotherapy
Funding Source:	Rhone-Poulenc Rorer
Role:	PI

Date:	1991
Title:	NO TITLE PROVIDED
Funding Source:	TJ Brown and CA Lupton Foundation, Inc. Research Grant
Role:	PI

Date:	1990 - 1995
Title:	Gemcitabine Difluorodeoxycytidine Phase I/II Weekly X 3 Every Four Weeks in Patients With NSCLC
Funding Source:	Eli Lilly and Company
Role:	PI

Date:	1990 - 1991
Title:	Phase II Study of LY186641 for Patients With Advanced (Stage IIIb or IV) or Recurrent Non-small Cell Lung Cancer
Funding Source:	Eli Lilly and Company
Role:	PI

Date:	1990 - 1992
Title:	Phase I Study of Multidose Sm-153-EDTMP for the Treatment of Metastatic Bone Disease
Funding Source:	Marion Merrell Dow Inc
Role:	PI

Date:	1986 - 1987
Title:	NO TITLE PROVIDED
Funding Source:	American Cancer Society Clinical Fellowship
Role:	Investigator

Title:	Couple-based meditation program for lung cancer patients and partners
Funding Source:	American Cancer Society (ACS)
Role:	Consult
ID:	13457

Selected Publications

Peer-Reviewed Articles

Zhou N, Leung CH, William WN Jr, Weissferdt A, Pataer A, Godoy MCB, Carter BW, Fossella FV, Tsao AS, Blumenschein GR, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Tran HT, Wu J, Solis Soto LM, Kadara H, Swisher SG, Vaporciyan AA, Gibbons DL, Lin HY, Lee JJ, Heymach JV, Negrao MV, Sepesi B, Cascone T. Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer. J Immunother Cancer 12(10), 2024. e-Pub 2024. PMID: 39448200.
Pan K, Owens J, Elamin Y, Lu C, Routbort M, Zhang J, Fossella, F T, Negrao MV, Altan M, Pozadzides J, Skoulidis F, Tsao A, Cascone T, Heymach JV, Ostrin E, Le X. Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma With EGFR Germline Mutations. J Thorac Oncol. e-Pub 2024. PMID: 38866326.
Chang, JY, Lin, SH, Dong, W, Liao, Z, Gandhi, S, Gay, CM, Zhang, J, Chun, SG, Elamin, YY, Fossella, FV, Blumenschein, GR, Cascone, T, Le, X, Pozadzides, JV, Tsao, A, Verma, V, Welsh, J, Chen, A, Altan, M, Mehran, RJ, Vaporciyan, AA, Swisher, SG, Balter, PA, Fujimoto, J, Wistuba, I, Feng, L, Lee, JJ, Heymach, JV. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer. The Lancet 402(10405):871-881, 2023. e-Pub 2023. PMID: 37478883.
Altan, M, Tu, J, Milton, D, Yilmaz, B, Tian, Y, Fossella, FV, Mott, FE, Blumenschein, GR, Stephen, B, Karp, DD, Meric-Bernstam, F, Heymach, JV, Naing, A. Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non–small cell lung cancer. Cancer 129(17):2685-2693, 2023. e-Pub 2023. PMID: 37129197.
Wang K, Du R, Roy-Chowdhuri S, Li ZT, Hong L, Vokes N, Elamin YY, Hume CB, Skoulidis F, Gay CM, Blumenschein G, Fossella, F T, Tsao A, Zhang J, Karachaliou N, O'Brate A, Gann CN, Lewis J, Rinsurongkawong W, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Altan M, Le X. Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC. JTO Clin Res Rep 4(8):100533, 2023. e-Pub 2023. PMID: 37649681.
Offodile AC, Delgado D, Lin YL, Geyen D, Miller CJ, Jain S, Finder JP, Shete S, Fossella, F T, Overman MJ, Peterson SK. Integration of Remote Symptom and Biometric Monitoring Into the Care of Adult Patients With Cancer Receiving Chemotherapy-A Decentralized Feasibility Pilot Study. JCO Oncol Pract 19(6):e811-e821, 2023. e-Pub 2023. PMID: 36821818.
Hanna N, Shepherd FA, Fossella, FV T, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TCY, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA. Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy. J Clin Oncol 41(15):2682-2690, 2023. e-Pub 2023. PMID: 37196429.
Cascone T, Leung CH, Weissferdt A, Pataer A, Carter BW, Godoy MCB, Feldman H, William WN, Xi Y, Basu S, Sun JJ, Yadav SS, Rojas Alvarez FR, Lee Y, Mishra AK, Chen L, Pradhan M, Guo H, Sinjab A, Zhou N, Negrao MV, Le X, Gay CM, Tsao AS, Byers LA, Altan M, Glisson BS, Fossella, F T, Elamin YY, Blumenschein G, Zhang J, Skoulidis F, Wu J, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Rajaram R, Antonoff MB, Fujimoto J, Solis LM, Parra ER, Haymaker C, Wistuba II, Swisher SG, Vaporciyan AA, Lin HY, Wang J, Gibbons DL, Jack Lee J, Ajami NJ, Wargo JA, Allison JP, Sharma P, Kadara H, Heymach JV, Sepesi B. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med 29(3):593-604, 2023. e-Pub 2023. PMID: 36928818.
Liu Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella FV, Gibbons DL, Kurie JM, Lu C, Skoulidis F, Chang JY, Liao Z, Gomez DR, O'Reilly M, Heymach JV, Tsao AS, Lin SH. Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial. Lung Cancer 174:112-117, 2022. e-Pub 2022. PMID: 36371941.
Hui D, Puac V, Shelal Z, Dev R, Hanneman SK, Jennings K, Ma H, Urbauer DL, Shete S, Fossella FV, Liao Z, Blumenschein G, Chang JY, O'Reilly M, Gandhi SJ, Tsao A, Mahler DA, Bruera E. Effect of dexamethasone on dyspnoea in patients with cancer (ABCD): a parallel-group, double-blind, randomised, controlled trial. Lancet Oncol 23(10):1321-1331, 2022. e-Pub 2022. PMID: 36087590.
Elamin YY, Robichaux JP, Carter BW, Altan M, Tran H, Gibbons DL, Heeke S, Fossella FV, Lam VK, Le X, Negrao MV, Nilsson MB, Patel A, Vijayan RSK, Cross JB, Zhang J, Byers LA, Lu C, Cascone T, Feng L, Luthra R, San Lucas FA, Mantha G, Routbort M, Blumenschein G, Tsao AS, Heymach JV. Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. Cancer Cell 40(7):754-767.e6, 2022. e-Pub 2022. PMID: 35820397.
Elamin YY, Robichaux JP, Carter BW, Altan M, Gibbons DL, Fossella FV, Lam VK, Patel AB, Negrao MV, Le X, Mott FE, Zhang J, Feng L, Blumenschein G, Tsao AS, Heymach JV. Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial. J Clin Oncol 40(7):JCO2101113, 2022. e-Pub 2022. PMID: 34550757.
Lin SH, Lin HY, Verma V, Xu-Welliver M, Thall PF, Yao L, Kim PY, Gombos DS, Kawedia JD, Komaki R, Gomez DR, Nguyen QN, O'Reilly MS, Lu C, Fossella FV, Skoulidis F, Zhang J, Tsao AS, Heymach JV, Blumenschein GR. Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer. Cancer Treat Res Commun 30:100514, 2022. e-Pub 2022. PMID: 35051703.
Malek AE, Khalil M, Hachem R, Chaftari AM, Fares J, Jiang Y, Kontoyiannis DP, Fossella F, Chaftari P, Mulanovich VE, Viola GM, Raad II. Impact of Checkpoint Inhibitor Immunotherapy Primarily Pembrolizumab on Infection Risk in Patients with Advanced Lung Cancer: A Comparative Retrospective Cohort Study. Clin Infect Dis 73(9):e2697-e2704, 2021. e-Pub 2021. PMID: 32564081.
Patel RR, He K, Barsoumian HB, Chang JY, Tang C, Verma V, Comeaux N, Chun SG, Gandhi S, Truong MT, Erasmus JJ, Hong DS, Lee PP, Ning MS, Nguyen QN, Heymach JV, Altan M, Blumenschein G, Fossella FV, Sezen D, Chen D, Carter BW, Davies MA, Glitza IC, Diab A, Ferrarotto R, Cabanillas ME, Yuan Y, Shah SJ, Parra ER, Sun B, Cortez MA, Welsh JW. High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial. Radiother Oncol 162:60-67, 2021. e-Pub 2021. PMID: 34237343.
Tran HT, Lam VK, Elamin YY, Hong L, Colen R, Elshafeey NA, Hassan ISA, Altan M, Blumenschein GR, Rinsurongkawong W, Rivera MJ, Vasquez ME, Carter BW, Byers LE, Tsao AS, Gibbons DL, Fossella F, Glisson BS, Zhang J, Heymach JV. Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling. JCO Precis Oncol 5, 2021. e-Pub 2021. PMID: 34377884.
Cascone T, William WN, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, Khan MAW, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, |Fossella FV, Mott FE, Tsao AS, Blumenschein G, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi B. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med 27(3):504-514, 2021. e-Pub 2021. PMID: 33603241.
Gjyshi O, Xu T, Elhammali A, Boyce-Fappiano D, Chun SG, Gandhi S, Lee P, Chen AB, Lin SH, Chang JY, Tsao A, Gay CM, Zhu XR, Zhang X, Heymach JV, |Fossella FV, Lu C, Nguyen QN, Liao Z. Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC. J Thorac Oncol 16(2):269-277, 2021. e-Pub 2021. PMID: 33198942.
Hong L, Negrao MV, Dibaj SS, Chen R, Reuben A, Bohac JM, Liu X, Skoulidis F, Gay CM, Cascone T, Mitchell KG, Tran HT, Le X, Byers LA, Sepesi B, Altan M, Elamin YY, |Fossella FV, Kurie JM, Lu C, Mott FE, Tsao AS, Rinsurongkawong W, Lewis J, Gibbons DL, Glisson BS, Blumenschein GR, Roarty EB, Futreal PA, Wistuba II, Roth JA, Swisher SG, Papadimitrakopoulou VA, Heymach JV, Lee JJ, Simon GR, Zhang J. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol 15(9):1449-1459, 2020. e-Pub 2020. PMID: 32389639.
Cascone T, Sepesi B, Lin HY, Kalhor N, Parra ER, Jiang M, Godoy MCB, Zhang J, |Fossella FV, Tsao AS, Lam VK, Lu C, Mott FE, Simon GR, Antonoff MB, Mehran RJ, Rice DC, Behrens C, Weissferdt A, Moran C, Vaporciyan AA, Lee JJ, Swisher SG, Gibbons DL, Wistuba II, William WN, Heymach JV. A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer. Clin Cancer Res 26(14):3525-3536, 2020. e-Pub 2020. PMID: 32193228.
Lin SH, Lin Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, |Fossella F, Gibbons DL, Kurie JM, Lu C, Simon G, Skoulidis F, Chang JY, Jeter MD, Liao Z, Gomez DR, O'Reilly M, Papadimitrakopoulou V, Thall P, Heymach JV, Tsao AS. Phase II Trial of Concurrent Atezolizumab with Chemoradiation for Unresectable NSCLC. J Thorac Oncol 15(2):248-257, 2020. e-Pub 2020. PMID: 31778797.
Tsao AS, Miao J, Wistuba II, Vogelzang NJ, Heymach JV, |Fossella FV, Lu C, Velasco MR, Box-Noriega B, Hueftle JG, Gadgeel S, Redman MW, Gandara DR, Kelly K. Phase II Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905). J Clin Oncol 37(28):2537-2547, 2019. e-Pub 2019. PMID: 31386610.
Hui D, Kilgore K, Park M, Liu D, Kim YJ, Park JC, |Fossella F, Bruera E. Pattern and Predictors of Outpatient Palliative Care Referral Among Thoracic Medical Oncologists. Oncologist 23(10):1230-1235, 2018. e-Pub 2018. PMID: 29895629.
Liao Z, Lee JJ, Komaki R, Gomez DR, O'Reilly MS, Fossella FV, Blumenschein GR, Heymach JV, Vaporciyan AA, Swisher SG, Allen PK, Choi NC, DeLaney TF, Hahn SM, Cox JD, Lu CS, Mohan R. Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 36(18):JCO2017740720, 2018. e-Pub 2018. PMID: 29293386.
Jeter MD, Gomez D, Nguyen QN, Komaki R, Zhang X, Zhu X, O'Reilly M, Fossella FV, Xu T, Wei X, Wang H, Yang W, Tsao A, Mohan R, Liao Z. Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study. Int J Radiat Oncol Biol Phys 100(3):730-737, 2018. e-Pub 2018. PMID: 29248169.
Cascone T, Gold KA, Swisher SG, Liu DD, Fossella FV, Sepesi B, Pataer A, Weissferdt A, Kalhor N, Vaporciyan AA, Hofstetter WL, Wistuba II, Heymach JV, Kim ES, William WN. Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer. Ann Thorac Surg 105(2):418-424, 2018. e-Pub 2018. PMID: 29217088.
Schvartsman G, Peng SA, Bis G, Lee JJ, Benveniste MFK, Zhang J, Roarty EB, Lacerda L, Swisher S, Heymach JV, Fossella FV, William WN. Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer 112:90-95, 2017. e-Pub 2017. PMID: 29191606.
Papadimitrakopoulou V, Lee JJ, Wistuba II, Tsao AS, Fossella FV, Kalhor N, Gupta S, Byers LA, Izzo JG, Gettinger SN, Goldberg SB, Tang X, Miller VA, Skoulidis F, Gibbons DL, Shen L, Wei C, Diao L, Peng SA, Wang J, Tam AL, Coombes KR, Koo JS, Mauro DJ, Rubin EH, Heymach JV, Hong WK, Herbst RS. The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients with Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. e-Pub 2016. PMID: 27480147.
Hui D, Kilgore K, Frisbee-Hume S, Park M, Tsao A, Delgado Guay M, Lu C, William W, Pisters K, Eapen G, Fossella F, Amin S, Bruera E. Dexamethasone for Dyspnea in Cancer Patients: A Pilot Double-Blind, Randomized, Controlled Trial. J Pain Symptom Manage 52(1):8-16.e1, 2016. e-Pub 2016. PMID: 27330023.
Shah MH, Lorigan P, O'Brien ME, Fossella FV, Moore KN, Bhatia S, Kirby M, Woll PJ. Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors. Invest New Drugs 34(3):290-9, 2016. e-Pub 2016. PMID: 26961907.
Hui D, Bansal S, Park M, Reddy A, Cortes J, Fossella F, Bruera E. Differences in attitudes and beliefs toward end-of-life care between hematologic and solid tumor oncology specialists. Ann Oncol 26(7):1440-6, 2015. e-Pub 2015. PMID: 26041765.
Gomez DR, Gladish GW, Wei X, Kotamarti KR, Allen PK, Cox JD, O'Reilly MS, Erasmus JJ, Fossella FV, Komaki R. Prognostic value of positron emission tomography/computed tomography findings in limited-stage small cell lung cancer before chemoradiation therapy. Am J Clin Oncol 37(1):77-80, 2014. e-Pub 2014. PMID: 23111360.
Blumenschein GR, Saintigny P, Liu S, Kim ES, Tsao AS, Herbst RS, Alden C, Lee JJ, Tang X, Stewart DJ, Kies MS, Fossella FV, Tran HT, Mao L, Hicks ME, Erasmus J, Gupta S, Girard L, Peyton M, Diao L, Wang J, Davis SE, Minna JD, Wistuba I, Hong WK, Heymach JV, Lippman SM. Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin Cancer Res 19(24):6967-75, 2013. e-Pub 2013. PMID: 24166906.
Milbury K, Badr H, Fossella F, Pisters KM, Carmack CL. Longitudinal associations between caregiver burden and patient and spouse distress in couples coping with lung cancer. Support Care Cancer 21(9):2371-9, 2013. e-Pub 2013. PMID: 23546537.
Laporte S, Squifflet P, Baroux N, Fossella F, Georgoulias V, Pujol JL, Douillard JY, Kudoh S, Pignon JP, Quinaux E, Buyse M. Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials. BMJ Open 3(3), 2013. e-Pub 2013. PMID: 23485717.
Pataer A, Kalhor N, Correa AM, Raso MG, Erasmus JJ, Kim ES, Behrens C, Lee JJ, Roth JA, Stewart DJ, Vaporciyan AA, Wistuba II, Swisher SG, |Fossella F. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol 7(5):825-32, 2012. e-Pub 2012. PMID: 22481232.
Shirvani SM, Komaki R, Heymach JV, Fossella FV, Chang JY. Positron Emission Tomography/Computer Tomography-Guided Intensity-Modulated Radiotherapy for Limited Stage Small Celll Lung Cancer. Int J Radiat Oncol Biol Phys 82(1):e91-e97, 2012. e-Pub 2012. PMID: 21489716.
Jr BG, Reck M, Fossella F, Stewart DJ, Lathia C, Peña C. Plasma biomarkers correlating with clinical outcome in a phase II study of sorafenib in advanced NSCLC. Cancer Biomark 10(6):287-298, 2012. e-Pub 2012.
Tsao AS, Liu S, Fujimoto J, Wistuba II, Lee JJ, Marom EM, Charnsangavej C, Fossella FV, Tran HT, Blumenschein GR, Papadimitrakopoulou V, Kies MS, Hong WK, Stewart DJ. Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J Thorac Oncol 6(12):2104-2111, 2011. e-Pub 2011.
Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella FV, Kies M, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK. The BATTLE Trial: Personalizing Therapy for Lung Cancer. Cancer Discovery 1(1):44-53, 2011. e-Pub 2011.
Blumenschein GR, Paulus R, Curran WJ, Robert F, Fossella F, Werner-Wasik M, Herbst RS, Doescher PO, Choy H, Komaki R. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B: non-small cell lung cancer: RTOG 0324. J Clin Oncol 29(17):2312, 2011. e-Pub 2011. PMID: 21555682.
Scagliotti G, Brodowicz T, Shepherd FA, Zielinski C, Vansteenkiste J, Manegold C, Simms L, Fossella F, Sugarman K, Belani CP. Treatment by histology interaction analyses in three phase III trials show superiority of pemetrexed in non-squamous non-small cell lung cancer. J Thorac Oncol 6(1):64-84, 2011. e-Pub 2011. PMID: 21119545.
William WN, Uyeki J, Johnson FM, Feng L, Peeples BO, Fossella FV, Karp DD, Blumenschein GR, Stewart DJ, Glisson BS. Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin the treatment of patients with extensive small cell lung cancer. Cancer 116(10):2409-15, 2010. e-Pub 2010. PMID: 20225329.
William WN, Kies MS, Fossella FV, Liu DD, Gladish G, Tse WH, Lee JJ, Hong WK, Lippman SM, Kim ES. Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer. Cancer 116(10):2401-8, 2010. e-Pub 2010. PMID: 20225327.
Jr WW, Uyeki J, Johnson FM, Feng L, Peeples BO, Fossella FV, Karp DD, Blumenschein GR, Stewart DJ, Glisson BS. Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma. Cancer 10(2409-2415), 2010. e-Pub 2010.
William WN, Khuri FR, Fossella FV, Glisson BS, Zinner RG, Lee JJ, Herbst RS, Lippman SM, Kim ES. Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small cell lung cancer as front-line and second-line therapy. Am J Clin Oncol 33(2):148-152, 2010. e-Pub 2010. PMID: 19687727.
Wilson C, Leaning D, Shankland K, Langheinrich T, Batty R, Fossella FV, Woll PJ. Cortical Blindness as an Unusual Adverse Drug Reaction. J Med Cases 1(2):47-50, 2010. e-Pub 2010.
Jr BG, Gatzemeier U, Fossella F, Stewart DJ, Cupit L, Cihon F, O'Leary J, Reck M. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 27(26):4274-4280, 2009. e-Pub 2009.
Jr BG, Gatzemeier U, Fossella F, stewart DJ, Cupit L, Cihon F, O'Leary J, Reck M. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small cell lung cancer. J Clin Oncol 27(26):4274-80, 2009. e-Pub 2009. PMID: 19652055.
Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, Simms L, Shepherd FA. The differential efficacy of pemetrexed according to NSCLC histology: A review of two Phase III studies. Oncologist 14(3):253-63, 2009. e-Pub 2009.
Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, Simms L, Shepherd FA. The differential efficacy of pemetrexed according to NSCLC histology: A review of two Phase III studies. Oncologist 14(3):253-263, 2009. e-Pub 2009.
Zinner RG, Komaki R, Cox JD, Glisson BS, Pisters KM, Herbst RS, Kies M, Liao Z, Hong WK, Fossella FV. Dose Escalation of Gemcitabine Is Possible with Concurrent Chest Three-Dimensional Rather than Two-Dimensional Radiotherapy: A Phase I Trial in Patients with Stage III Non-Small-Cell Lung Cancer. Int J Radiat Oncol Biol Phys 73(1):119-27, 2009. e-Pub 2009. PMID: 18556142.
Rice D, Swisher S, Pisters K, Fossella F, Herbst R, Hofstetter W, Kies M, Komaki R, Lippman S, Mehran R, Roth J, Stewart D, Vaporciyan A, Walsh G, Cox J. Comment on "Treatment of non-small cell lung cancer stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition)". Chest 134(6):1349; author reply 1350, 2008. e-Pub 2008. PMID: 19059972.
Carmack Taylor CL, Badr H, Lee JH, Fossella F, Pisters K, Gritz ER, Schover L. Lung cancer patients and their spouses: Psychological and relationship functioning within one month of treatment initiation. Ann Behav Med 36(2)(2):129-140, 2008. e-Pub 2008. PMID: 18797978.
Carmack Taylor CL, Badr H, Lee JH, Fossella F. Lung cancer patients and their spouses: psychological and relationship functioning with one month of treatment initiation. Ann Behav Med 3(11):129-40, 2008. e-Pub 2008.
Carmack Taylor CL, Badr H, Lee JH, Fossella F, Pisters K, Gritz ER, Schover L. Lung cancer patients and their spouses: psychological and relationship functioning within 1 month of treatment initiation. Ann Behav Med 36(2):129-140, 2008. e-Pub 2008.
Kalemkerian GP, Akerlely W, Downey RJ, Ettinger DS, Fossella F, Grecula JC, Jahan T, Johnson BE, Kessinger A, Koczywas M, Langer DJ, Martins R, Niell HB, CCk P, Ramnath N, Ready N, Robert F, Jr WC. Small Cell Lung Cancer. J Natl Compr Cancer Netw 6(3):204-314, 2008. e-Pub 2008. PMID: 18377848.
Kennedy MP, Jimenez CA, Chang J, Fossella F, Eapen GA, Morice RC. Optimisation of bronchial brachytherapy catheter placement with a modified airway stent. Eur Respir J 31(4):902-3, 2008. e-Pub 2008. PMID: 18378785.
de Marinis F, Pereira JR, Fossella F, Perry MC, Reck M, Salzberg M, Jassem J, Peterson P, Liepa AM, Moore P, Gralla RJ. Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer. J Thorac Oncol 3(1):30-6, 2008. e-Pub 2008. PMID: 18166838.
Douillard JY, Laporte S, Fossella F, Georgoulias V, Pujol JL, Kubota K, Monnier A, Kudoh S, Rubio JE, Cucherat M. Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials. J Thorac Oncol 2(10):939-46, 2007. e-Pub 2007. PMID: 17909357.
Huang EH, Liao Z, Cox JD, Guerrero TM, Chang JY, Jeter M, Borghero Y, Wei X, Fossella F, Herbst RS, Blumenschein GR, Moran C, Allen PK, Komaki R. Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone. Int J Radiat Oncol Biol Phys 68(3):779-85, 2007. e-Pub 2007. PMID: 17418967.
Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, Radosavljevic D, Paccagnella A, Zatloukal P, Mazzanti P, Bisset D, Rosell R, Group CM. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 99(11):847-57, 2007. e-Pub 2007. PMID: 17551145.
Weiss GJ, Rosell R, Fossella F, Perry M, Stahel R, Barata F, Nguyen B, Paul S, McAndrews P, Hanna N, Kelly K, Bunn PA. The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small cell lung cancer. Ann Oncol 18(3):453-60, 2007. e-Pub 2007. PMID: 17322539.
Altundag O, Stewart DJ, Fossella FV, Ayers GD, Wei W, Zhou X, Zinner RG. Many patients 80 years and older with advanced non-small cell lung cancer (NSCLC) can tolerate chemotherapy. J Thorac Oncol 2(2):141-6, 2007. e-Pub 2007. PMID: 17410030.
Fanucchi MP, Fossella FV, Belt R, Natale R, Fidias P, Carbone DP, Govindan R, Raez LE, Robert F, Ribeiro M, Akerley W, Kelly K, Limentani SA, Crawford J, Reimers HJ, Axelrod R, Kashala O, Sheng S, Schiller JH. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol 24(31):5025-33, 2006. e-Pub 2006. PMID: 17075122.
Belani CP, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Fossella F, group TAX. Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial. Lung Cancer 53(2):231-9, 2006. e-Pub 2006. PMID: 16787687.
Johnson BE, Crawford J, Downey RJ, Ettinger DS, Fossella F, Grecula JC, Jahan T, Kalemkerian GP, Kessinger A, Koczywas M, Langer CJ, Martins R, Marymont MH, Niell HB, Ramnath N, Robert F, Williams CC, Cancer Network NC. Small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw 4(6):602-22, 2006. e-Pub 2006. PMID: 16813728.
Montoya M, Fossella F, Palmer JL, Kaur G, Pace EA, Yadav R, Simmonds M, Gillis T, Bruera E. Objective evaluation of physical function in patients with advanced lung cancer: a preliminary report. J Palliat Med 9(2):309-16, 2006. e-Pub 2006. PMID: 16629561.
Thomas SK, Fossella FV, Liu D, Schaerer R, Tsao AS, Kies MS, Pisters KM, Blumenschein GR, Glisson BS, Lee JJ, Herbst RS, Zinner RG. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer 7(5):326-31, 2006. e-Pub 2006. PMID: 16640804.
Belani CP, Fossella F. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer 104(12):2766-74, 2005. e-Pub 2005. PMID: 16288485.
Zinner RG, Fossella FV, Gladish GW, Glisson BS, Blumenschein GR, Papadimitrakopoulou VA, Pisters KM, Kim ES, Oh YW, Peeples BO, Ye Z, Curiel RE, Obasaju CK, Hong WK, Herbst RS. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer 104(11):2449-56, 2005. e-Pub 2005. PMID: 16258975.
Robert F, Blumenschein G, Herbst RS, Fossella FV, Tseng J, Saleh MN, Needle M. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol 23(36):9089-96, 2005. e-Pub 2005. PMID: 16301597.
Kim ES, Kies MS, Fossella FV, Glisson BS, Zaknoen S, Statkevich P, Munden RF, Summey C, Pisters KM, Papadimitrakopoulou V, Tighiouart M, Rogatko A, Khuri FR. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma. Cancer 104(3):561-9, 2005. e-Pub 2005. PMID: 16028213.
Liao Z, Komaki R, Milas L, Yuan C, Kies M, Chang JY, Jeter M, Guerrero T, Blumenschein G, Smith CM, Fossella F, Brown B, Cox JD. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer. Clin Cancer Res 11(9):3342-8, 2005. e-Pub 2005. PMID: 15867233.
Komaki R, Chang JY, Wu X, Allen PK, Milas L, Liao Z, Fossella FV, Travis E, Spitz MR. Mutagen sensitivity may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer treated by chemoradiotherapy. Semin Oncol 32(2 Suppl 3):S92-8, 2005. e-Pub 2005. PMID: 16015542.
Chang JY, Komaki R, Sasaki R, Liao Z, Stevens CW, Lu C, Fossella FV, Allen PK, Cox JD, Spitz MR, Wu X. High mutagen sensitivity in peripheral blood lymphocytes predicts poor overall and disease-specific survival in patients with stage III non-small cell lung cancer treated with radiotherapy and chemotherapy. Clin Cancer Res 11(8):2894-8, 2005. e-Pub 2005. PMID: 15837739.
Tran HT, Blumenschein GR, Lu C, Meyers CA, Papadimitrakopoulou V, Fossella FV, Zinner R, Madden T, Smythe LG, Puduvalli VK, Munden R, Truong M, Herbst RS. Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. Cancer Chemother Pharmacol 54(4):308-14, 2004. e-Pub 2004. PMID: 15184994.
Kim ES, Putnam JB, Komaki R, Walsh GL, Ro JY, Shin HJ, Truong M, Moon H, Swisher SG, Fossella FV, Khuri FR, Hong WK, Shin DM. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer 44(3):369-79, 2004. e-Pub 2004. PMID: 15140551.
Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22(9):1589-97, 2004. e-Pub 2004. PMID: 15117980.
Khuri FR, Glisson BS, Kim ES, Statkevich P, Thall PF, /ML M, Herbst RS, Munden RF, Tendler C, Zhu Y, Bangert S, Thompson E, Lu C, Wang XM, Shin DM, Kies MS, Papadimitrakopoulou V, Fossella FV, Kirschmeier P, Bishop WR, Hong WK. Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors. Clin Cancer Res 10(9):2968-76, 2004. e-Pub 2004. PMID: 15131032.
Komaki R, Lee JS, Milas L, Lee HK, Fossella FV, Herbst RS, Allen PK, Liao Z, Stevens CW, Lu C, Zinner RG, Papadimitrakopoulou VA, Kies MS, Blumenschein GR, Pisters KM, Glisson BS, Kurie J, Kaplan B, Garza VP, Mooring D, Tucker SL, Cox JD. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys 58(5):1369-77, 2004. e-Pub 2004. PMID: 15050312.
Zinner RG, Glisson BS, Fossella FV, Pisters KM, Kies MS, Lee PM, Massarelli E, Sabloff B, Fritsche HA, Ro JY, Ordonez NG, Tran HT, Yang Y, Smith TL, Mass RD, Herbst RS. Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. Lung Cancer 44(1):99-110, 2004. e-Pub 2004. PMID: 15013588.
Taylor NA, Liao ZX, Cox JD, Stevens C, Roth J, Walsh G, Chang JY, Guerrero T, Jeter M, Putnam J, Fossella FV, Allen P, Komaki R. Equivalent outcome of patients with clinical Stage IIIA non-small-cell lung cancer treated with concurrent chemoradiation compared with induction chemotherapy followed by surgical resection. Int J Radiat Oncol Biol Phys 58(1):204-12, 2004. e-Pub 2004. PMID: 14697440.
Komaki R, Chasen MH, Travis WD, Putnam JB, Fossella FV, Byhardt RW, Ro JY. Oncodiagnosis panel: 1999. Cancer of the lung: oncodiagnosis. Radiographics 21(6):1573-1596, 2003. e-Pub 2003. PMID: 11706227.
Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Belani CP. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 21(16):3016-24, 2003. e-Pub 2003. PMID: 12837811.
Taylor NA, Liao ZX, Stevens C, Walsh G, Roth J, Putnam J, Fossella F, Allen P, Cox JD, Komaki R. Postoperative radiotherapy increases locoregional control of patients with stage IIIA non-small-cell lung cancer treated with induction chemotherapy followed by surgery. Int J Radiat Oncol Biol Phys 56(3):616-25, 2003. e-Pub 2003. PMID: 12788166.
Johnson FM, Kurie JM, Peeples BO, Lee JJ, Feng L, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer. Clin Lung Cancer 5(1):40-5, 2003. e-Pub 2003. PMID: 14596703.
Lu C, Komaki R, Lee JS, Shin DM, Palmer JL, Coldman BJ, Pisters KM, Kurie JM, Fossella FV, Glisson BS. A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer. Clin Cancer Res 9(6):2085-91, 2003. e-Pub 2003. PMID: 12796372.
Massarelli E, Andre F, Liu DD, Lee JJ, Wolf M, Fandi A, Ochs J, Le Chevalier T, Fossella F, Herbst RS. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 39(1):55-61, 2003. e-Pub 2003. PMID: 12499095.
Swisher SG, Roth JA, Komaki R, Gu J, Lee JJ, Hicks M, Ro JY, Hong WK, Merritt JA, Ahrar K, Atkinson NE, Correa AM, Dolormente M, Dreiling L, El-Naggar AK, Fossella F, Francisco R, Glisson B, Grammer S, Herbst R, Huaringa A, Kemp B, Khuri FR, Kurie JM, Liao Z, McDonnell TJ, Morice R, Morello F, Munden R, Papadimitrakopoulou V, Pisters KM, Putnam JB, Sarabia AJ, Shelton T, Stevens C, Shin DM, Smythe WR, Vaporciyan AA, Walsh GL, Yin M. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res 9(1):93-101, 2003. e-Pub 2003. PMID: 12538456.
Herbst RS, Madden TL, Tran HT, Blumenschein GR, Meyers CA, Seabrooke LF, Khuri FR, Puduvalli VK, Allgood V, Fritsche HA, Hinton L, Newman RA, Crane EA, Fossella FV, Dordal M, Goodin T, Hong WK. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. J Clin Oncol 20(22):4440-7, 2002. e-Pub 2002. PMID: 12431966.
Herbst RS, Khuri FR, Lu C, Liu DD, Fossella FV, Glisson BS, Pisters KM, Shin DM, Papadimitrakopoulou VA, Kurie JM, Blumenschein G, Kies MS, Zinner R, Jung MS, Lu R, Lee JJ, Munden RF, Hong WK, Lee JS. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. Cancer 95(2):340-53, 2002. e-Pub 2002. PMID: 12124835.
Liao Z, Komaki R, Stevens C, Kelly J, Fossella F, Lee JS, Allen P, Cox JD. Twice daily irradiation increases locoregional control in patients with medically inoperable or surgically unresectable stage II-IIIB non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 53(3):558-65, 2002. e-Pub 2002. PMID: 12062597.
Fossella FV. Docetaxel in second-line treatment of non-small-cell lung cancer. Clin Lung Cancer 3 Suppl 2:S23-8, 2002. e-Pub 2002. PMID: 14720344.
Komaki R, Lee JS, Kaplan B, Allen P, Kelly JF, Liao Z, Stevens CW, Fossella FV, Zinner R, Papadimitrakopoulou V, Khuri F, Glisson B, Pisters K, Kurie J, Herbst R, Milas L, Ro J, Thames HD, Hong WK, Cox JD. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results. Semin Radiat Oncol 12(1 Suppl 1):46-9, 2002. e-Pub 2002. PMID: 11917284.
Kim E, Mauer A, Fossella F, Kies M, Tran H, Purdom M, Gladish G, Needle M, Vokes E, Herbst R. A phase II study of erbitux, an epidermal growth factor receptor blocking antibody, in combination with docetaxelin chemotherapy refractory/resistant patients with advanced non-small cell lung cancer. Eur J Cancer 38:153, 2002. e-Pub 2002.
Herbst RS, Khuri FR, Fossella FV, Glisson BS, Kies MS, Pisters KM, Riddle JR, Terry KA, Lee JS. ZD1839 (Iressa) in non-small-cell lung cancer. Clin Lung Cancer 3(1):27-32, 2001. e-Pub 2001. PMID: 14656386.
Blumenschein GR, Khuri FR, Fossella FV, Lee JS, Shin DM, Liu D, Lu C, Munden RF, Lu R, Lee J, Hong WK, Herbst RS. Final report of the M.D. Anderson phase II study of combination weekly gemcitabine and vinorelbine in patients with untreated or previously treated non-small cell lung cancer (Poster presentation). Proc ASCO 20:344a, 2001. e-Pub 2001.
Komaki R, Cos JD, Putnam JB, Walsh G, Vaporcian A, Liao Z, Stevens C, Fossella FV, Lee JS, Hong WK, Roth J. The management of superior sulcus tumors. J Jpn Soc Ther Radiol Oncol 13:1231, 2001. e-Pub 2001.
Perez-Cardona JH, Ordonez NG, Fossella FV. Lymph node micrometastases in non-small cell lung cancer: clinical applications. Clin Lung Cancer 2(2):116-20, 2000. e-Pub 2000. PMID: 14731321.
Komaki R, Roth JA, Walsh GL, Putnam JB, Vaporciyan A, Lee JS, Fossella FV, Chasen M, Delclos ME, Cox JD. Outcome predictors for 143 patients with superior sulcus tumors treated by multidisciplinary approach at the University of Texas M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys 48(2):347-54, 2000. e-Pub 2000. PMID: 10974447.
Oh Y, Perez-Soler R, Fossella FV, Glisson BS, Kurie J, Walsh GL, Truong M, Shin DM. Phase II study of intravenous Doxil in malignant pleural mesothelioma. Invest New Drugs 18(3):243-5, 2000. e-Pub 2000. PMID: 10958592.
Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18(12):2354-62, 2000. e-Pub 2000. PMID: 10856094.
Nemunaitis J, Swisher SG, Timmons T, Connors D, Mack M, Doerksen L, Weill D, Wait J, Lawrence DD, Kemp BL, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam JB, Richli WR, Shin DM, Walsh GL, Merritt J, Roth J. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol 18(3):609-22, 2000. e-Pub 2000. PMID: 10653876.
Herbst RS, Khuri FR, Jung M, Fossella FV, Lee JS, Glisson BS, Pisters KM, Shin DM, Pisters K, Papadimitrakopoulou V, Kurie J, Perez-Soler R, Liu D, Lu C, Zinner R, Guerra M, Munden R, Hong WK. Phase II study of combination weekly gemcitabine and vinorelbine in patients with untreated or previously treated non-small cell lung cancer. Lung Cancer 29(1):12 (suppl 1), 2000. e-Pub 2000.
Perez-Cardona J, Ordonez NJ, Pisters KMW, Putnam JB, Fossella FV. Immunohistochemical evaluation of mediastinoscopy-negative lymph nodes in the staging of patients with non-small cell lung cancer (submitted for publication). J Thor Cardiovasc Surg, 2000. e-Pub 2000.
Lee JS, Pisters KM, Komaki R, Terry K, Glisson BS, Perez-Soler R, Fossella FV, Shin DM, Herbst RS, Khuri FR, Kurie JM, Hong WK. Systemic chemotherapy as a primary treatment of brain metastasis in patients with non-small cell lung cancer. Lung Cancer 29(1):4 (suppl 1), 2000. e-Pub 2000.
Leighl NB, Shepherd FA, Tsao SW, Lindgren P, Belani C, Fossella FV, Goodwin PJ. An economic analysis of the TAX326 trial: a multicenter randomized study of docetaxel + cisplatin or docetaxel + carboplatin versus vinorelbine + cisplatin as first-line therapy in advanced non-small cell lung cancer (submitted for publication). J Clin Oncol, 2000. e-Pub 2000.
Liu NS, Spitz MR, Kemp BL, Cooksley C, Fossella FV, Lee JS, Hong WK, Khuri FR. Adenocarcinoma of the lung in young patients: The M. D. Anderson experience. Cancer 88(8):1837, 2000. e-Pub 2000. PMID: 10760760.
Belani C, Fossella FV. Should elderly patients with advanced non-small cell lung cancer receive chemotherapy? (submitted for publication). Cancer, 2000. e-Pub 2000.
Belani C, Pereira JR, von Pawel J, Gauting AF, Poluzanska A, Kaukel E, Mattson K, Ramlau R, Fidias P, Millward M, Fossella F. Effect of chemotherapy for advanced non-small cell lung cancer on patient's qualify of life. J Clin Oncol, 2000. e-Pub 2000.
Glisson BS, Kurie JM, Perez-Soler R, Fox NJ, Murphy WK, Fossella FV, Lee JS, Ross MB, Nyberg DA, Pisters KM, Shin DM, Hong WK. Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma. J Clin Oncol 17(8):2309-15, 1999. e-Pub 1999. PMID: 10561292.
Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH, Connors DG, El-Naggar AK, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Mack M, Merritt JA, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam JB, Richli WR, Savin M, Schrump DS, Shin DM, Shulkin A, Walsh GL, Wait J, Weill D, Waugh MK. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 91(9):763-71, 1999. e-Pub 1999. PMID: 10328106.
Lee JS, Komaki R, Fossella FV, Glisson BS, Hong WK, Cox JD. A pilot trial of hyperfractionated thoracic radiation therapy with concurrent cisplatin and oral etoposide for locally advanced inoperable non-small-cell lung cancer: a 5-year follow-up report. Int J Radiat Oncol Biol Phys 42(3):479-86, 1998. e-Pub 1998. PMID: 9806504.
Roth JA, Atkinson EN, Fossella F, Komaki R, Bernadette Ryan M, Putnam JB, Lee JS, Dhingra H, De Caro L, Chasen M, Hong WK. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 21(1):1-6, 1998. e-Pub 1998. PMID: 9792048.
Khuri FR, Fossella FV, Lee JS, Murphy WK, Shin DM, Markowitz AB, Glisson BS. Phase II trial of recombinant IFN-alpha2a with etoposide/cisplatin induction and interferon/megestrol acetate maintenance in extensive small cell lung cancer. J Interferon Cytokine Res 18(4):241-5, 1998. e-Pub 1998. PMID: 9568726.
Glisson B, Komaki R, Lee JS, Shin DM, Fossella F, Murphy WK, Kurie J, Perez-Soler R, Schea R, Vadhan-Raj S. Integration of filgrastim into chemoradiation for limited small cell lung cancer: a Phase I study. Int J Radiat Oncol Biol Phys 40(2):331-6, 1998. e-Pub 1998. PMID: 9457817.
Glisson B, Lee JS, Palmer J, Fossella F, Shin DM, Murphy WK, Perez-Soler R, Hong WK. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma. Cancer 82(2):301-8, 1998. e-Pub 1998. PMID: 9445186.
Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16(1):187-96, 1998. e-Pub 1998. PMID: 9440742.
Haskell CM, Mendoza E, Pisters KM, Fossella FV, Figlin RA. Phase II study of intravenous adenosine 5'-triphosphate in patients with previously untreated stage IIIB and stage IV non-small cell lung cancer. Invest New Drugs 16(1):81-5, 1998. e-Pub 1998. PMID: 9740548.
Shade RJ, Pisters KM, Huber MH, Fossella F, Perez-Soler R, Shin DM, Kurie J, Glisson B, Lippman S, Lee JS. Phase I study of paclitaxel administered by ten-day continuous infusion. Invest New Drugs 16(3):237-43, 1998. e-Pub 1998. PMID: 10360603.
Komaki R, Scott C, Ettinger D, Lee JS, Fossella FV, Curran W, Evans RF, Rubin P, Byhardt RW. Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer: Radiation Therapy Oncology Group (RTOG) 92-04. Int J Radiat Oncol Biol Phys 38(1):149-55, 1997. e-Pub 1997. PMID: 9212017.
Fossella FV, Lippman SM, Shin DM, Tarassoff P, Calayag-Jung M, Perez-Soler R, Lee JS, Murphy WK, Glisson B, Rivera E, Hong WK. Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. J Clin Oncol 15(1):310-6, 1997. e-Pub 1997. PMID: 8996158.
Fossella FV. Single agent docetaxel in patients with refractory non-small cell lung cancer. Oncology 11(suppl 7):11, 1997. e-Pub 1997.
Demetri G, Elias A, Gershenson D, Fossella F, Grecula J, Mittal B, Raschko J, Robertson J. NCCN Small-Cell Lung Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park) 10(11 Suppl):179-94, 1996. e-Pub 1996. PMID: 8953602.
Perez-Soler R, Glisson BS, Lee JS, Fossella FV, Murphy WK, Shin DM, Hong WK. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol 14(10):2785-90, 1996. e-Pub 1996. PMID: 8874340.
Lee JS, Scott C, Komaki R, Fossella FV, Dundas GS, McDonald S, Byhardt RW, Curran WJ. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: radiation therapy oncology group protocol 91-06. J Clin Oncol 14(4):1055-64, 1996. e-Pub 1996. PMID: 8648357.
Perez-Soler R, Fossella FV, Glisson BS, Lee JS, Murphy WK, Shin DM, Kemp BL, Lee JJ, Kane J, Robinson RA, Lippman SM, Kurie JM, Huber MH, Raber MN, Hong WK. Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol 14(2):503-13, 1996. e-Pub 1996. PMID: 8636764.
Huber MH, Lee JS, Newman RA, Fossella FV, Wester M, Hong WK, Lippman SM. A phase I investigation of the sequential use of methotrexate and paclitaxel with and without G-CSF for the treatment of solid tumors. Ann Oncol 7(1):59-63, 1996. e-Pub 1996. PMID: 9081393.
Shin DM, Fossella FV, Umsawasdi T, Murphy WK, Chasen MH, Walsh G, Komaki R, McMurtrey MJ, Hong WK. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma. Cancer 76(11):2230-6, 1995. e-Pub 1995. PMID: 8635025.
Lee JS, Newman RA, Lippman SM, Fossella FV, Calayag M, Raber MN, Krakoff IH, Hong WK. Phase I evaluation of all-trans retinoic acid with and without ketoconazole in adults with solid tumors. J Clin Oncol 13(6):1501-8, 1995. e-Pub 1995. PMID: 7751898.
Komaki R, Shin DM, Glisson BS, Fossella FV, Murphy WK, Garden AS, Oswald MJ, Hong WK, Roth JA, Peters LJ. Interdigitating versus concurrent chemotherapy and radiotherapy for limited small cell lung cancer. Int J Radiat Oncol Biol Phys 31(4):807-11, 1995. e-Pub 1995. PMID: 7860392.
Fossella FV, Lee JS, Murphy WK, Lippman SM, Calayag M, Pang A, Chasen M, Shin DM, Glisson B, Benner S. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 12(6):1238-44, 1994. e-Pub 1994. PMID: 7911160.
Roth JA, Fossella F, Komaki R, Ryan MB, Putnam JB, Lee JS, Dhingra H, De Caro L, Chasen M, McGavran M. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 86(9):673-80, 1994. e-Pub 1994. PMID: 8158698.
Bayouth JE, Macey DJ, Kasi LP, Fossella FV. Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases. J Nucl Med 35(1):63-9, 1994. e-Pub 1994. PMID: 7505819.
Goeckeler WF, Stoneburner LK, Kasi LP, Fossella FV, Price DR, Fordyce WA. Analysis of urine samples from metastatic bone cancer patients administered 153Sm-EDTMP. Nucl Med Biol 20(5):657-61, 1993. e-Pub 1993. PMID: 8358352.
Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, Davilla E, Leimert J, Dhingra H, Raber MN. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 85(5):384-8, 1993. e-Pub 1993. PMID: 8094466.
Munshi NC, Seitz DE, Fossella F, Lippman SM, Einhorn LH. Phase II study of sulofenur (LY 186641). A novel antineoplastic agent in advanced non-small cell lung cancer. Invest New Drugs 11(1):87-90, 1993. e-Pub 1993. PMID: 8394298.
Lee JS, Libshitz HI, Fossella FV, Murphy WK, Pang AC, Lippman SM, Shin DM, Dimery IW, Glisson BS, Hong WK. Improved therapeutic index by leucovorin of edatrexate, cyclophosphamide, and cisplatin regimen for non-small-cell lung cancer. J Natl Cancer Inst 84(13):1039-40, 1992. e-Pub 1992. PMID: 1318977.
Shin DM, Dhingra HM, Lee JS, Fossella FV, Murphy WK, Hong WK. Phase II study of combination therapy with high-dose cisplatin, etoposide, and mitomycin in patients with advanced non-small-cell lung cancer. Am J Clin Oncol 15(3):194-9, 1992. e-Pub 1992. PMID: 1317094.
Fossella FV, Winn RJ, Holoye PY, Raber MN, Holden L, Belt R, Allen H, Hallinan B, Harper K. Phase II trial of intravenous 6-thioguanine for unresectable or metastatic non-small cell bronchogenic carcinoma. Invest New Drugs 9(4):375-6, 1991. e-Pub 1991. PMID: 1666631.
Fossella FV, Lippman SM, Seitz DE, Alberts DS, Taylor CW, Wiltshaw E, Hardy J, O'Brien M, Haynes TR, Wolen RL. Hypoprothrombinemia from coadministration of sulofenur (LY 186641) and warfarin: report of three cases. Invest New Drugs 9(4):357-9, 1991. e-Pub 1991. PMID: 1804813.
Lee JS, Libshitz HI, Fossella FV, Murphy WK, Pang AC, Lippman SM, Shin DM, Dimery IW, Glisson BS, Hong WK. Edatrexate improves the antitumor effects of cyclophosphamide and cisplatin against non-small cell lung cancer. Cancer 68(5):959-64, 1991. e-Pub 1991. PMID: 1655220.
Ellerbroek NA, Fossella FV, Rich TA, Ajani JA, Komaki R, Roth JA, Holoye PY. Low-dose continuous infusion cisplatin combined with external beam irradiation for advanced colorectal adenocarcinoma and unresectable non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys 20(2):351-5, 1991. e-Pub 1991. PMID: 1846848.
Tuma SN, Orson F, Fossella FV, Waidhofer W. Seizures and dermatitis after exposure to caprolactam. Arch Intern Med 141(11):1544-5, 1981. e-Pub 1981. PMID: 7283571.

Invited Articles

Johnson FM, Kurie JM, Peeples BO, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer. Oncology (Williston Park) 17(7 Suppl 7):17-21, 2003. e-Pub 2003. PMID: 12886869.
Fossella FV. Docetaxel for previously treated non-small-cell lung cancer. Oncology (Williston Park) 16(6 Suppl 6):45-51, 2002. e-Pub 2002. PMID: 12108897.
Fossella FV, Gatzemeier U. Phase I trials of pemetrexed. Semin Oncol 29(2 Suppl 5):8-16, 2002. e-Pub 2002. PMID: 12023787.
Khuri FR, Herbst RS, Fossella FV. Emerging therapies in non-small-cell lung cancer. Ann Oncol 12(6):739-44, 2001. e-Pub 2001. PMID: 11484947.
Shepherd FA, Fossella FV, Lynch T, Armand JP, Rigas JR, Kris MG. Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: A review of two Phase III trials. Semin Oncol 28(1 Suppl 2):4-9, 2001. e-Pub 2001. PMID: 11284623.
Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L, Study Group TRT. A randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced NSCLC previously treated with platinum-containing chemotherapy regimens. J Clin Oncol Classic Papers Current Comments 6:97, 2001. e-Pub 2001.
Fossella FV. Second-line chemotherapy for non-small-cell lung cancer. Curr Oncol Rep 1(1):1, 2001. e-Pub 2001. PMID: 11122830.
Fossella FV. Docetaxel in the treatment of non-small cell lung cancer: review of single-agent trials. Semin Oncol 26(5 Suppl 16):17-23; discussion 41-2, 1999. e-Pub 1999. PMID: 10585004.
Fossella FV, Rigas J. The use of docetaxel (Taxotere) in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. Semin Oncol 26(3 Suppl 11):9-12, 1999. e-Pub 1999. PMID: 10458204.
Fossella FV. Overview of docetaxel (Taxotere) in the treatment of non-small cell lung cancer. Semin Oncol 26(3 Suppl 11):4-8, 1999. e-Pub 1999. PMID: 10458203.
Roth JA, Swisher SG, Merritt JA, Lawrence DD, Kemp BL, Carrasco CH, El-Naggar AK, Fossella FV, Glisson BS, Hong WK, Khurl FR, Kurie JM, Nesbitt JC, Pisters K, Putnam JB, Schrump DS, Shin DM, Walsh GL. Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement. Semin Oncol 25(3 Suppl 8):33-7, 1998. e-Pub 1998. PMID: 9704675.
Lee JS, Pisters KM, Komaki R, Glisson BS, Khuri FR, Schea R, Fossella FV. Paclitaxel/carboplatin chemotherapy as primary treatment of brain metastases in non-small cell lung cancer: a preliminary report. Semin Oncol 24(4 Suppl 12):S12-52-S12-55, 1997. e-Pub 1997. PMID: 9331122.
Fossella FV, Lee JS, Hong WK. Management strategies for recurrent non-small cell lung cancer. Semin Oncol 24(4):455-62, 1997. e-Pub 1997. PMID: 9280225.
Perez-Soler R, Glisson BS, Lee JS, Fossella FV, Murphy WK, Shin DM, Hong WK. Treatment of patients with small cell lung cancer refractory to etoposide with the topoisomerase I poison Topotecan. J Clin Oncol Classic Papers and Current Comments 2:96, 1997. e-Pub 1997.
Fossella FV, Lee JS, Shin DM, Calayag M, Huber M, Perez-Soler R, Murphy WK, Lippman S, Benner S, Glisson B. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small cell lung cancer. J Clin Oncol 2:229, 1997. e-Pub 1997.
Fossella FV, Lee JS, Berille J, Hong WK. Summary of phase II data of docetaxel (Taxotere), an active agent in the first- and second-line treatment of advanced non-small cell lung cancer. Semin Oncol 22(2 Suppl 4):22-9, 1995. e-Pub 1995. PMID: 7740327.
Fossella FV, Lee JS, Shin DM, Calayag M, Huber M, Perez-Soler R, Murphy WK, Lippman S, Benner S, Glisson B. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 2(3):229, 1995. e-Pub 1995. PMID: 7884425.

Review Articles

Waxman ES, Fossella FV. Biomarkers/Molecular Targets, Immunotherapy, and Treatments for Non-Small Cell Lung Cancer. J Adv Pract Oncol 7(5):514-524, 2016. e-Pub 2016. PMID: 29282427.
Hellmann MD, Chaft JE, William WN, Rusch V, Pisters KM, Kalhor N, Pataer A, Travis WD, Swisher SG, Kris MG, |Fossella F. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol 15(1):e42-50, 2014. e-Pub 2014. PMID: 24384493.
Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 6(4):229-39, 2005. e-Pub 2005. PMID: 15811618.
Zinner RG, |Fossella FV, Herbst RS. Pemetrexed in advanced NSCLC: a review of the clinical data. Oncology (Williston Park) 18(8 Suppl 5):54-62, 2004. e-Pub 2004. PMID: 15339061.
Murray N, Salgia R, Fossella FV. Targeted molecules in small cell lung cancer. Semin Oncol 31(1 Suppl 1):106-11, 2004. e-Pub 2004. PMID: 14981588.
Fossella FV. Pemetrexed for treatment of advanced non-small cell lung cancer. Semin Oncol 31(1 Suppl 1):100-5, 2004. e-Pub 2004. PMID: 14981587.
Fossella F, Rigas JR, Belani CP. New options in the treatment of non-small cell lung cancer. Anticancer Drugs 10 Suppl 1:S25-8, 1999. e-Pub 1999. PMID: 10630365.
Fossella FV, Rivera E, Roth JA. Preoperative chemotherapy for stage IIIa non-small cell lung cancer. Curr Opin Oncol 8(2):106-11, 1996. e-Pub 1996. PMID: 8727302.
Lenzi R, Fossella FV, Lee JS. Systemic treatment of non-small-cell lung cancer. Compr Ther 18(3):27-30, 1992. e-Pub 1992. PMID: 1315236.

Professional Educational Materials

Fossella FV. Lung Cancer (patient teaching aid), 2008.
Fossella FV. Questions and Answers about non-small cell and small cell lung cancer (patient teaching aid), 2008.
Fossella FV. Malignant Pleural Mesothelioma (patient teaching aid), 2008.
Kalemkerian GP, Akerley W, Downey RJ, Ettinger DS, Fossella F, Grecula JC, Jahan T, Johnson BE, Kessinger A, Koczywas M, Langer CJ, Martins R, Niell HB, Pan CC, Ramnath N, Ready N, Robert F, Williams CC. Treatment Guidelines for Patients. Version III. Lung Cancer, 2007.
Kalemkerian GP, Akerley W, Downey RJ, Ettinger DS, Fossella F, Grecula JC, Jahan T, Johnson BE, Kessinger A, Koczywas M, Langer CJ, Martins R, Niell HB, Pan CC, Ramnath N, Ready N, Robert F, Williams CC. NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer, 2007.
Fossella FV, Waxman E. Living with Lung Cancer, 2001.
Fossella FV. Treating Non-Small Cell Lung Cancer, 2001.
Fossella FV. Development of Thoracic Oncology Practice Guidelines and Collaborative Care Paths, Pathfinder, 2000.
Fossella FV. NCI PDQ/PIF Computerized Patient Information Project, 2000.
Fossella FV. Assistance of Office of Patient Education in Project, Assessing Hispanic Cancer Patients' Needs at Different Stages of Cancer, 2000.
Fossella FV. Collaborator in preparation of patient education and resource manual, A Caring Community: Guidebook to Resources for Patients with Advanced Cancer and Their Caregivers, 2000.
Fossella FV. Voice Your Choice with Advance Directives, 1998.
Fossella FV. Single-agent docetaxel in patients with refractory Non-small cell lung cancer, 1998.
Fossella FV. Dose/duration intensity studies with gemcitabine. In: Lilly Oncology Global Medical Conference. Adelphi Communications, Ltd, 1995.
Fossella FV. Expert Panelist, “Lung Cancer: Taking Control. Nationwide Summit on Lung Cancer” live satellite video conference, 1977.

Editorials

Rice D, Swisher S, Pisters K, Fossella F, Herbst R, Hoffstetter W, Kies M, Komake R, Lippman S, Mehran R, Roth J, Stewart D, Vaprociyan A, Walsh G, Cox J. Comment on "Treatment of non-small cell lung cancer stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition. Chest 34(6):1350, 2008. PMID: 19059972.

Abstracts

Tang C, de Groot P, Hess K, Shabaan S, Gomez D, Chang J, Lin S, Paraskevopoulos T, Raju U, Simon G, Papadimitrakopoulou V, Liao Z, Fossella F, Glisson B, Komaki R, Hahn S, Heymach J, Welsh J. Phase I study of pembrolizumab and stereotactic or hypofractionated radiation for metastatic non-small cell lung cancer. ASCO Annual Meeting 2017, 2017. e-Pub 2017.
Papadimitrakopoulou V, Lee JJ, Wistuba II, Tsao AS, Fossella FV, Kalhor N, Gupta S, Byers LA, Izzo JG, Gettinger SN, Goldberg SB, Tang X, Miller VA, Skoulidis F, Gibbons DL, Shen L, Wei C, Diao L, Peng SA, Wang J, Tam AL, Coombes KR, Koo JS, Mauro DJ, Rubin EH, Heymach JV, Hong WK, Herbst RS. The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients with Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2016. e-Pub 2016. PMID: 27480147.
Hui D, Kilgore K, Frisbee-Hume S, Park M, Tsao A, Delgado Guay M, Lu C, Jr WW, Pisters K, Eapen G, Fossella F, Amin S, Bruera E. Dexamethasone for Dyspnea in Cancer Patients: A Pilot Double-Blind, Randomized, Controlled Trial. J Pain Symptom Manage, 2016. e-Pub 2016. PMID: 27330023.
Shah MH, Lorigan P, O'Brien ME, Fossella FV, Moore KN, Bhatia S, Kirby M, Woll PJ. Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors. Invest New Drugs, 2016. e-Pub 2016. PMID: 26961907.
Hui D, Bansal S, Park M, Reddy AS, Cortes JE, Fossella FV, Bruera E. Differences in attitudes and beliefs toward end-of-life treatments between hematologic (Heme) and solid tumor (ST) oncology specialists. ASCO Meeting Abstracts 2015; J Clin Oncol 33(15_suppl):9524, 2015. e-Pub 2015.
Yennu S, Fossella FV, Williams JL, Berg EA, Mewenenessi TA, Hui D, Tanco KC, Chisholm GB, Vidal, M, Cantu H, Guerra-Sanchez M, Young AM, Reddy SK, Bruera E. Outcomes of early palliative care referrals for patients with advanced lung cancer. ASCO Meeting Abstracts 2014; J Clin Oncol 32(15_suppl):9625, 2014. e-Pub 2014.
Papadimitrakopoulou V, Lee JJ, Wistuba II, Tsao AS, Fossella FV, Heymach J, Kalhor N, Gupta S, Gettinger SN, Byers LA, Izzo J, Miller VA, Diao L, Wang J, Coombes KR, Mauro DJ, Rubin EH, Hong WK, Herbst RS. BATLLE-2: KRAS mutation and outcome in a biomarker-integrated study in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 2014; J Clin Oncol 32(15_suppl):8042, 2014. e-Pub 2014.
Tran HT, Melnikova VO, Tsao AS, |Fossella FV, Johnson FM, Papadimitrakopoulou V, Garza M, Neal C, Hasegawa D, Kruempel A, Wu G, Richardson K, Lewis ME, Legendre Jr B, Anderes KL, Davis DW, Heymach J. Characterization and identification of specific EGFR mutations in circulating tumor cells (CTCs) isolated from non-small cell lung cancer patients using antibody independent method, ApoStream. Abstracts 2013; J Clin Oncol 31(15_suppl):11044, 2013. e-Pub 2013.
Papadimitrakopoulou V, Wistuba II, Lee JJ, Tsao AS, Kalhor N, |Fossella FV, Heymach J, Alden CM, Gettinger SN, Coombes KR, Saintigny P, Tang X, Duffield E, Boyer J, Davis SE, Powis G, Mauro DJ, Rubin EH, Hong WK, Herbst RS. BATTLE-2 program: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 2013; J Clin Oncol 31(15_suppl):TPS8118, 2013. e-Pub 2013.
Blumenschein GR, Molina JR, Lathia CD, Ong TJ, Roth D, Rajagopalan P, |Fossella FV, Kies MS, Marks RS, Adjei AA, Sundaresan PR. Phase I dose-escalation study of sorafenib in combination with bevacizumab (B), paclitaxel (P) and carboplatin (C) for the treatment of advanced nonsquamous non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 2011; J Clin Oncol 29(15_suppl):7565, 2011. e-Pub 2011.
Woll PJ, Moore N, Bhatia S, |Fossella FV, Chen LC, O'Brien M, Lorigan P, Weitman SD, O'Leary JJ, Zildjian S, Bulger E, Guild R, Shah MH. Efficacy results from phase I study of lorvotuzumab mertansine (IMGN901) in patients with CD56-positive solid tumors. ASCO Meeting Abstracts 2011; J Clin Oncol 29(15_suppl):e13582, 2011. e-Pub 2011.
Komaki R, Wei X, Allen P, Roth A, Swisher S, Rice DC, Walsh GL, |Fossella FV, Erasmus JJ, Cox JD. Treatment for superior sulcus tumors (SST): Effect of surgery first followed by adjunct concurrent chemoradiotherapy on survivial of patients with marginally resectable SST. JCO 28(15S), 2010. e-Pub 2010.
Gomez DR, Gladish GW, Wei X, Allen P, Cox JD, O'reilly M, Erasmus JJ, |Fossella F, Komaki R. Pretreatment positron emission tomography (PET) scan standardized uptake value (SUV) as a prognostic variable for overall survival in limited-stage small cell lung cancer (L-SCLC). JCO 28(15S), 2010. e-Pub 2010.
Zinner R, Herbst RS, Fossella FV, Johnson FM, Karp DD, Kies MS, Heymach JV, Price JS, Lippman SM, Erasmus, Jr, J. Results from short-term CT assessments in patients with advanced poor performance status non-small cell lung cancer (NSCLC receiving pemetrexed in a phase II trial. JCO 27(15S), 2009. e-Pub 2009.
Woll PJ, Moore KN, Bhatia S, |Fossella FV, Chen LC, O'. Phase I dose-escalation study of sorafenib in combination with bevacizumab (B), paclitaxel (P), and carboplatin (C) for the treatment of advanced nonsquamous non-small cell lung cancer (NSCLC. JCO 29(15S), 2009. e-Pub 2009.
Komaki R, Allen PI, Wei X, Liao Z, Chang JY, Thames H, Glisson B, Fossella FV, Oh Y, Ohnishi K, Cox J. Prognostic factors identified in the long-term survivors with limited small cell lung cancer. J Clin Oncol 26, 2008. e-Pub 2008.
Buyse M, Squifflet P, Laporte S, Fossella FV, Georgoulias V, Pujol J, Kubota K, Monnier A, SKudoh, Douillard J. Prediction of survival benefits from progression-free survival i patients with advanced non-small cell lung cancer: Evidence from a pooled analysis of 2,838 patients randomized in7 trials. J Clin Oncol 26, 2008. e-Pub 2008.
Blumenschein G, Paulus R, Curran W, Rober F, Fossella FV, Werner-Wasik, Doescher P, Choy H, Komaki R. A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) i patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): A report of the 2 year and median survival (MS) for the RTOG 0324 trial. J Clin Onc 26, 2008. e-Pub 2008.
McCann J, Fossella FV, Villalona-Calero MA, Tolcher AW, Fidias P, Raju R, Zildjian S, Guild R, Fram R. Phase II trial of huN901-DM1 in patients with relapsed small cell lung cancer (SCLC) and CD56-positive small cell carcinoma). Proc Am Soc of Cln Onc Abstract # 18084, 2007. e-Pub 2007.
Uyeki J, Johnson FM, Feng L, Peeples BO, Blumenschein GJ, Fossella FV, Karp DD, Pisters KM, Stewart DJ, Glisson BS. Phase II trial of irinotecan plus cisplatin (IP) and etoposide plus cisplatin (EP) given weekly on alternating weeks with granulocyte colony-stimulating factor support in the treatment of extensive-stage small cell lung cancer. Proc Am Soc of Clin Onc Abstract 18149, 2007. e-Pub 2007.
Jr BG, Moughan J, Curran W, Robert F, Fossella FV, Werner-Wasik M, Doescher P, Choy H, Komaki R. A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (pts) with stage III A/B non-small cell lung cancer (NSCLC): An interim report of the RTOG 0324. Proc Am Soc of Clin Onc Abstract 7531, 2007. e-Pub 2007.
Jr WW, Kies MS, Fossella FV, Gladish G, Heymach JV, Glisson BS, Tse WH, Liu D, Herbst RS, Lippman SM. Phase II study of bevacizumab in combination with docetaxel and carboplatin in patients with metastatic non-small cell lung cancer (NSCLC). Proc Am Soc of Clin Onc Abstract # 18098, 2007. e-Pub 2007.
Zinner R, Fossella FV, Kies MS, Herbst RS, Lu C, Johnson FM, Bhat SV, Price JS, Cleeland C, Wang X. A phase IUI trial of pemetrexed (P) in patients (pts) with performance status (PS) 2 and 3 as first- and second-line treatment for advanced non-small cell lung cancer (NSCLC). Proc Am Soc of Clin Onc Abstract 18149, 2007. e-Pub 2007.
Fossella FV, Berry DA, Adachi S, McAndrews P, Peterson P. Survival in previously treated advanced NSCLC: Pemetrexed versus best supportive care (BSC). Proc AM Soc of Clin Onc Abstract 17015, 2006. e-Pub 2006.
Douillard JY, Fossella FV, Georgoulias V, Pujol JL, Zkubota K, Monnier A, Takeda K, Cucherat M, Laporte S. Comparison of docetaxel and vinca alkaloid, alone or in combination with other chemotherapy agents, in the first-line treatment of advanced non-small cell lung cancer (NSCLC): A meta-analysis. Proc Am Soc of Clin Onc Abstract 7034:Poster Discussion Presentation, 2006. e-Pub 2006.
Komaki R, Allen P, Glisson B, Lu C, Fossella FV, Liao Z, Jeter M, Stevens C, Chang J, Guerrero T, Blumenschein G. Hyperfractionated/accelerated thoracic radiation therapy (HFXRT) increased survival compared to daily RT (QDRT) for limited small cell lung cancer (LSCLC) with Concurrent Chemotherapy (ChT) (Poster presentation). Proc Am Soc of Clin Onc:Abstract 7158, 2005. e-Pub 2005.
Altundag O, Stewart DJ, Stevens C, Rice DC, Ayers GD, Blumenschein GR, Karp DD, Hong WK, Fossella FV, Zinner RG. The risk of distant metastases in patients with non-small cell lung cancer (NSCLC) with cytologically proven malignant pleural effusion, stage IIIB: A retrospective analysis. Proc Am Soc of Clin Onc:Abstract 7034, 2005. e-Pub 2005.
Fanucchi MP, Fossella FV, Fidias P, Natale RB, Belt RJ, Carbone DP, Govindan R, Raez L, Robert F, Schiller J. Bortezomib ± docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): A phase 2 study (Poster discussion presentation). Proc Am Soc of Clin Onc:Abstract 7034, 2005. e-Pub 2005.
Fossella FV, McCann J, Tolcher A, Xie H, Hwang LL, Carr C, Berg K, Fram R. Phase II trial of B-10901 (huN901-DM1) given weekly for four consecutive weeks every 6 weeks in patients with relapsed SCLC and CD56-positive small cell carcinoma. Proc Am Soc of Clin Onc:Abstract 7159, 2005. e-Pub 2005.
Stewart D, Fossella FV, Willcutt N, Keck JG, Brown GL, Papadimitrakopoulou V. Phase II dose-ranging study of TLK286 a novel glutathione analog prodrug in combination with cisplatin as first-line treatment in locally advanced or metastatic non-small cell lung cancer (NSCLC) (Poster presentation). Proc Am Soc of Clin Onc:Abstract 7126, 2005. e-Pub 2005.
Pujol JL, Shaharyar S, Kortsik C, Wu MF, Bagnes C, Barata F, Kayitalire L, Hong S, Shepherd F, |Fossella F. Post study docetaxel in non-small cell lung cancer (NSCLC) patients after discontinuation from a randomized phase III trial of pemetrexed versus docetaxel: An exploratory analysis. Proc Am Soc of Clin Onc:Abstract 7135, 2004. e-Pub 2004.
Fanucchi MP, Belt RJ, |Fossella FV, Natale RB, Robert F, Fidias P, Kelly K, Kashala O, Schenkein DP, Schiller JH. Phase (ph) 2 study of bortexomib ± docetaxel in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC): Preliminary results. Proc Am Soc of Clin Onc:Abstract 7107, 2004. e-Pub 2004.
Komaki R, Spitz MR, Wu X, Chang JY, Allen PK, Lika M, |Fossella FV, Stevens CW, Liao Z, Cox JD. Mutagen Sensitivity (MS) may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer (NSCLC) treated by chemoradiotherapy. Proc Am Soc of Clin Onc:Abstract 7232, 2004. e-Pub 2004.
Koshy S, Herbst RS, Obasaju CK, Fossella FV, Papadimitrakopoulou V, Pisters KMW, Blumenschein G, Peeples BO, Hong WK, Zinner RG. A phase II trial of pemetrexed (P) plus carboplatin (C) in patients (pts) with advanced non-small-cell lung cancer (NSCLC). Proc Am Soc of Clin Onc:Abstract 7074, 2004. e-Pub 2004.
Fossella FV, Obasaju C, Paul S. Pemetrexed vs docetaxel for non-small cell lung cancer (NSCLC): Could vitamin supplementation affect docetaxel survival? An exploratory analysis. Proc Am Soc of Clin Onc:Abstract 7131, 2004. e-Pub 2004.
Zinner R, Obasaju CK, Fossella FV, Papadimitrakopoulou VA, Pisters KMW, O’Day MR, Peeples BO, Hatfield AK, Hong WK, Herbst RS. Alimta plus carboplatin (AC) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): A phase II trial. Proc ASCO 22:642, 2003. e-Pub 2003.
Hanna NH, Shepherd FA, Rosell R, Pereira JR, De Marinis F, |Fossella F, Kayitalire L, Paul S, Einhorn LH, Bunn PA. A phase III study of Pemetrexed vs docetaxel in patients with recurrent non-small lung cancer (NSCLC) who were previously treated with chemotherapy. Proc ASCO 33:622, 2003. e-Pub 2003.
Fossella FV, Belani CP. Phase III study (TAX 326) of docetaxel-cisplatin (DC) and docetaxel-carboplatin (DCb) versus vinorelbine-cisplatin (VC) for the first-time treatment of advanced / metastatic non-small-cell lung cancer (NSCLC): Analyses in elderly patients. Proc ASCO 22:629, 2003. e-Pub 2003.
Tsao AS, Kim ES, Nazario A, Fossella FV, Glisson BS, Zinner R, Henderson T, Liu D, Papadimitrakopoulou V, Khuri FR. Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small lung cancer as frontline and second-line therapy. Proc ASCO 22:691, 2003. e-Pub 2003.
Yadav RR, Fossella F, Palmer JL, Simmonds M, Kaur G, Wiley J, Bruera E. An objective evaluation of functional ability (OEF) in patients with advanced lung cancer. Proc ASCO 22:746, 2003. e-Pub 2003.
Papadimitrakopoulou V, Figlin R, Garland L, Blumenschein G, Fossella FV, Von Hoff DD, King L, Brown GL, Mascavage J, Henner WD. Phase 2 study of TLK286 (GST P1-1 activated glutathione analog) administered weekly in patients with non-small cell lung cancer (NSCLC) who failed prior platinum-based regimens. Proc ASCO 22:355, 2003. e-Pub 2003.
Fossella FV, Lynch T, Shepherd FA. Second line chemotherapy for NSCLC: establishing a gold standard. Lung Cancer 38(suppl 4):5-12, 2003. e-Pub 2003.
Fossella FV, Lynch T, Shepherd FA. Second line chemotherapy for NSCLC: establishing a gold standard. Lung Cancer 38(suppl 4):5-12, 2002. e-Pub 2002. PMID: 12480189.
Rosell R, Fossella FV, Milas L. Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancer. Lung Cancer 38(suppl 4):43-49, 2002. e-Pub 2002. PMID: 12480194.
Kim ES, Mauer AM, Fossella FV, Jamison TA, Kies MS, Pisters KM, Glisson BS, Blumenschein GR, Zinner RG, Tran HT, Windt P, Liu D, Khuri F, Dicke K, Needle M, Vokes EE, Hong WK, Herbst RS. A phase II study of Erbitux (IMC-C225), an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory / resistant patients with advanced non-small cell lung cancer (NSCLC). Proc ASCO 21:293a, 2002. e-Pub 2002.
Blumenschein GR, Fossella FV, Pisters KMW, Khuri FR, Lu C, Kies MS, Glisson BS, Zinner R, Crane E, Schaerer R, Dordal M, Goodin T, Hong WK, Herbst RS. A phase I study of TNP-470 continuous infusion alone or in combination with paclitaxel and carboplatin in adult patients with NSCLC and other solid tumors. Proc ASCO 21:314a, 2002. e-Pub 2002.
Fossella FV, Tolcher A, Elliot M, Lambert JM, Lu R, Zinner R, Lu C, Oh Y, Forouzesh B, McCreary H, Rowinsky EK, Barrington P, Miller Y, Dawson K. Phase I trial of the monoclonal antibody conjugate, BB-10901, for relapsed / refractory small cell lung cancer (SCLC) and other neuroendocrine (NE) tumors. Proc ASCO 21:309a, 2002. e-Pub 2002.
Gralla RJ, Rodriguez J, Von Pawel J, Pluzanska A, Kaukel E, Mattson K, Fossella FV, Sczczesna A, Ramlau R, Lynch AT, Millward M, Belani CP. Prospective analysis of quality of life (QOL) in a randomized multinational phase III study comparing docetaxel (D) plus either cisplatin (C) or carboplatin (Cb) with vinorelbine plus cisplatin (VC) in patients with advanced non-small cell lung cancer (NSCLC). Proc ASCO 21:300a, 2002. e-Pub 2002.
Massarelli E, Andre F, Liu DD, Lee J, Fandi A, Ochs J, Le Chevalier T, |Fossella FV, Herbst RS. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including a platin and docetaxel for recurrent non-small-cell lung cancer. Proc ASCO 21:331a, 2002. e-Pub 2002.
Johnson FM, Kurie JM, Pisters KM, Fossella FV, Peeples BO, Papadimitrakopoulou VA, Blumenschein GR, Kies MS, Komaki R, Glisson BS. Phase I trial of weekly etoposide (E), cisplatin (P), and irinotecan (I) with G-CSF in patients with small-cell lung cancer (SCLC). Proc ASCO 21:312a, 2002. e-Pub 2002.
Komaki R, Lee JS, Kaplan B, Allen P, Kelly JF, Liao Z, Stevens CW, |Fossella FV, Papadimitrakopoulou VA, Khuri F, Glisson B, Pisters K, Cox JD. Randomized phase III study of chemoradiation ± amifostine in patients with inoperable stage II-III non-small cell lung cancer (NSCLC) (Poster presentation). Proc ASCO 20:325a, 2001. e-Pub 2001.
Rodriguez J, Pawel J, Pluzanska A, Gorbounova V, |Fossella F, Kaukei E, Mattson K, Millward M, Kim YS, Gamza F, Berille J, Belani CP. A multicenter, randomized phase III study of docetaxel + cisplatin (DC) and docetaxel + carboplatin (DCB) vs. vinorelbine + cisplatin (VC) in chemotherapy-naïve patients with advanced and metastatic non-small cell lung cancer. Proc ASCO 20:314a, 2001. e-Pub 2001.
Kim ES, Putnam JB, Komaki R, Walsh GL, Ro JY, Shin HJ, Moon H, Swisher SG, |Fossella FV, Khuri FR, Hong WK, Shin DM. A phase II study of multidisciplinary approach with induction chemotherapy (IC), followed by surgical resection (SR), radiation therapy (RT) and consolidation chemotherapy (CC) for unresectable malignant thymomas: final report. Proc ASCO 20:310a, 2001. e-Pub 2001.
Swisher S, Roth J, Komaki R, Hicks M, Ro J, Hong WK, Ahrar K, Correa A, Dolormente M, Dreiling L, Fang B, |Fossella F, Francisco R, Glisson B, Herbst R, Huaringa A, Gu J, Kelly J, Kemp B, Khuri F, Kurie J, Lee J, Lee JS, Liao Z, Merritt J, Morice R, Morello F, Mosheim M, Munden R, Papadimitrakopoulou V, Pisters K, Putnam J, Sarabia A, Shelton T, Stevens C, Shin D, Smythe W, Vaporciyan A, Walsh G, Yin M, Yver A. Induction of pro-apoptotic mediators and tumor regression following intratumoral delivery of adenoviral p53 (RPR/INGN 201) and radiation therapy in patients with non-small cell lung cancer (NSCLC) (Poster presentation). Proc ASCO 20:257a, 2001. e-Pub 2001.
Fossella FV, Zinner RG, Komaki R, Lu R, Lee JS, Glisson BS, Pisters KM, Stevens CW, Kurie JM, Kies MS, Khuri FR, Kelly J, Liao Z, Hong WK. Gemcitabine (G) with concurrent chest radiation (XRT) followed by consolidation chemotherapy with gemcitabine plus cisplatin (CDDP): a phase I trial for patients with stage III non-small cell lung cancer (NSCLC) (Poster presentation/ discussion). Proc ASCO 20:312a, 2001. e-Pub 2001.
Kim KB, Shin DM, Summey CC, Kurie JM, |Fossella FV, Lee JS, Zinner RG, Glisson BS, Kies MS, Hong WK, Abbruzzeese JL, Khuri FR. Phase I study of farnesyl transferase inhibitor, BMS-214662 in solid tumors. Proc ASCO 20:79a, 2001. e-Pub 2001.
Tran HT, Jr BG, Madden T, Shin DM, Khuri F, |Fossella F, Papadimitrakopoulou V, Lee J, Haas A, Dordal M, Hong WK, Herbst RS. Phase I study of the angiogenesis inhibitor TNP-470 in combination with paclitaxel (P) and carboplatin (CPt) in patients with solid tumors. Proc ASCO 20:99a, 2001. e-Pub 2001.
Fossella FV. Docetaxel + cisplatin and docetaxel + carboplatin vs vinorelbine + cisplatin in chemotherapy-naïve patients with advanced and metastatic non-small cell lung cancer. Eur J Cancer 7(suppl 6):S154, 2001. e-Pub 2001.
Fossella FV, Zinner RG, Komaki R, Lu R, Lee JS, Glisson BS, Pisters KM, Stevens CW, Kelly J, Liao Z. Gemcitabine with concurrent chest radiation followed by consolidation chemotherapy with gemcitabine plus cisplatin: a phase I trial for patients with stage III non-small cell lung cancer (Poster presentation). Eur J Cancer 7(suppl 6):S53, 2001. e-Pub 2001.
Komaki R, Roth J, Walsh GL, Putnam JR, Swisher S, Vaporciyan A, Lee JS, |Fossella F, Chasen M, Cox JD. Multidisciplinary approach for 143 patients with superior sulcus tumors treated at the University of Texas M.D. Anderson Cancer Center. Proc Jap Soc Therap Radiol Oncol 12:110, 2000. e-Pub 2000.
Herbst R, Tran H, Madden T, Khuri F, Meyers C, Shin D, Puduvalli V, Blumenschein G, Hinton L, Lee J, |Fossella F, Pisters K, Zinner R, Terry K. Phase I study of the angiogenesis inhibitor TNP-470 (T) in combination with paclitaxel (P) in patients with solid tumors. Proc ASCO 19:182a, 2000. e-Pub 2000.
Kim YP, Koch G, Shepherd FA, |Fossella F, Hammershaimb L, Gamza F, Rodgers A, Bizzari JP, Berille J, Durrleman S. Integrated analysis for two randomized phase III studies comparing Taxotere at 75 mg/m2 and 100 mg/m2 to control regimens in non-small cell lung cancer (NSCLC) patients previously treated with a platium-based chemotherapy. Lung Cancer 29(Lung Cancer):59, 2000. e-Pub 2000.
Lee J, Pisters K, Komaki R, Terry K, Glisson B, Perez-Soler R, |Fossella F, Shin D, Herbst R, Khuri F, Kurie J, Hong W. Paclitaxel and carboplatin chemotherapy as a primary treatment of brain metastases in patients with non-small cell lung cancer (NSCLC). Proc ASCO 19:501a, 2000. e-Pub 2000.
Zinner R, Fossella F, Komaki R, Jung M, Jhingran A, Glisson B, Pisters K, Stevens C, Khuri F, Kurie J, Lee J, Herbst R, Liao Z, Hong W. Gemcitabine with concurrent 3d conformal radiation followed by consolidation gemicitabine plus cisplatin; a phase I trial for patients with stage III non-small cell lung cancer (NSCLC). Proc ASCO 19:510a, 2000. e-Pub 2000.
Glisson B, Lee J, Shin D, |Fossella F, Palmer L, Coldman B, Komaki R. Topotecan/paclitaxel (TP) alternating with Etoposide/cisplatin (EC) and thoracic radiation (TRT) in patients with limited small-cell lung cancer (L-SCLC). Proc ASCO 19:493a, 2000. e-Pub 2000.
Shin DM, Walsh GL, Smythe WR, Ro J, Shin HJ, Swisher S, Lu C, |Fossella FV, Khuri FR, Yalamanchili A, Hong WK, Khokhar AR. Pathologic response with liposomal-entrapped cisplatin analog (L-NDDP) administered in patients (pts) with malignant pleural mesothelioma (MPM): phase II clinical study. Lung Cancer 29(suppl 1):19, 2000. e-Pub 2000.
Herbst RS, Khuri FR, Jung MS, |Fossella FV, Lee JS, Glisson B, Shin DM, Pisters K, Papadimitrakopoulou V, Kurie J, Perez-Soler R, Liu D, Lu C, Guerra M, Munden R, Hong WK. Phase II study of combination weekly gemcitabine and vinorelbine in patients with unteated or previsouly treated non-small cell lung cancer. Lung Cancer 29(suppl 1):12, 2000. e-Pub 2000.
Fossella FV, Zinner RG, Komaki R, Jung M, Jhingran A, Glisson BS, Pisters KM, Stevens CW, Khuri FR, Kuire JM, Lee JS, Herbst RS, Liao Z, Hong WK. Gemcitabine (G) with concurrent chest radiation (XRT) followed by consolidation chemotherapy with gemcitabine plus cisplatin (CDDP): a phase I trial for patients with stage III non-small cell lung cancer (NSCLC) (Poster presentation). Lung Cancer 29(suppl 1):111, 2000. e-Pub 2000.
Belani CP, Rodriguez J, von Pawel J, Plunzanska A, Gorbounova V, Millward M, Bosquee L, Kim Y, Gamza F, Berille J, Hammershaimb L, |Fossella F. A multicenter, randomized phase III study of docetaxel + cisplatin (DC) vs docetaxel + carboplatin (DCb) vs vinorelbine + cisplatin (VC) in chemotherapy-naïve patients (Pts) with advanced and metastatic non-small cell lung cancer (NSCLC00). Lung Cancer 29(suppl 1):60, 2000. e-Pub 2000.
Khuri FR, Glisson BS, Meyers ML, Herbst RS, Thall PF, Munden RF, Bangert S, Cascino M, Shin DM, Kurie JM, Papadimitrakopoulou V, |Fossella FV, Pisters KMW, Hong WK. Phase I study of farnesyl tranferase inhibitors (FTI) SCH66336 with paclitaxel in solid tumors: dose finding, pharmacokinetics, efficacy/safety. Lung Cancer 29(suppl 1):63, 2000. e-Pub 2000.
Fossella FV, DeVore R, Kerr R, Crawford J, Natale R, Dunphy F, Kalman L, Gandara D, Gamza F, Hammershaimb L, Kim Y, Crist W. Phase III trial of docetaxel 100 mg/m2 or 75 mg/m2 vs vinorelbine/ifosfamide for NSCLC previously treated with platinum-based chemotherapy (Slide presentation). Proc ASCO 18(460a), 1999. e-Pub 1999.
Lee JS, Komaki R, Touroutoglu N, Delclos M, Fox N, Glisson BS, Perez-Soler R, |Fossella FV, Khuri FR, Hong WK. Erythropoietin plus iron supplement prevents significant anemia during concurrent chemoradiation therapy in patients with locally advanced inoperable non-small cell lung cancer. Proc AACR 40:642, 1999. e-Pub 1999.
Zinner R, Fossella FV, Komaki R, Delclos M, Jung M, Glisson B, Lee JS, Pisters K, Jhingran A, Hong WK. Phase I trial of gemcitabine plus chest radiotherapy followed by consolidation systemic chemotherapy with gemcitabine plus cisplatin for patients with stage III and medically inoperable stage II NSCLC. Proc ASCO 18:446a, 1999. e-Pub 1999.
Kudelka AP, Verschraegen CF, Edwards CL, Freedman RS, Plunkett W, Ruiz van Haperen VWT, |Fossella F, Lifshitz F, Steger M, Voi M, Bast RC, Kavanaugh JJ. A Preliminary report of a phase 2 study of gemcitabine in women with platinum-refractory mullerian (ovarian, fallopian tube and primary peritoneal) carcinomas. Proc ASCO 17:367a, 1998. e-Pub 1998.
Shih N, Khuri FR, Fossella FV, Spitz MR, Cooksley C, Yu R, Lee JJ, Hong WK. Adenocarcinoma of the lung in young patients. Proc ASCO 17:459a, 1998. e-Pub 1998.
Levitt ML, Fossella FV, Devore RF. A randomized phase II study comparing 2 doses of gemcitabine in advanced or metastatic NSCLC: preliminary results. Proc ASCO 17:493a, 1998. e-Pub 1998.
Fossella F, Devore R, Kerr R, Crawford J, Natale R. Randomized phase III study of Taxotere (100 mg/m2 and 75 mg/m2) versus vinorelbine or ifosfamide in NSCLC patients, previously treated with platinum-based chemotherapy. Proc ASCO 14:483a, 1998. e-Pub 1998.
Coughlin SA, Kim YS, Gehrke ER, |Fossella FV. Effect of prophylactic G-CSF on the hematological safety profile of Taxotere in patients with advanced stage NSACLC. Proc ASCO 17:481a, 1998. e-Pub 1998.
Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Cassasco CH, Connors DG, El-Naggar AK, |Fossella FV, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Merritt JA, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KMW, Putnam JB, Richli WR, Schrump DS, Timmons T, Shin DM, Walsh GL, Waugh KA. Adenoviral-mediated p53 gene transfer in advanced non-small cell lung cancer. Proc ASCO 17:431a, 1998. e-Pub 1998.
Lee JS, Komaki R, Tourtougolou N, Delclos M, Fox N, Glisson BS, Perez-Soler R, |Fossella FV, Khuri FR, Hong WK. Erythropoietin prevents anemia during concurrent chemoradiation therapy for locally advanced inoperable NSCLC. Proc ASCO 17:463a, 1998. e-Pub 1998.
Perez-Soler R, Khuri F, Pisters KMW, Robinson R, Wimberly A, Lee JK, |Fossella FV. Phase II study of topotecan in patients with squamous carcinoma of the lung previously untreated with chemotherapy. Proc ASCO 16:450a, 1997. e-Pub 1997.
Qasim M, Valero V, Cohen P, |Fossella F, Bedekian A, Kavanagh J, Pazdur R. Cutaneous toxicity of docetaxel. Proc ASCO 16:248a, 1997. e-Pub 1997.
Fossella FV, Lee JS, Kau SW, Jung M, Raber M, Hong WK. Docetaxel for platinum-refractory non-small cell lung cancer: comparison of phase II results to historical controls. Proc ASCO 16:468a, 1997. e-Pub 1997.
Swisher SG, Roth JA, Lawrence DD, Kemp BL, Carrasco CH, |Fossella FV, Glisson BS, Hong WK, Khuri FK, Kurie JM, Nesbitt JC, Pisters KMW, Putnam JB, Walsh GW, Schrump DS, Shin DM, Walsh GL. Adenoviral-mediated p53 gene transfer in patients with advanced Non-small cell lung cancer. Proc ASCO 16:437a, 1997. e-Pub 1997.
Nguyen B, Voi M, Fossella FV, Levitt ML, Richards F. Integrated analyses of single-agent gemcitabine phase I studies in chemonaive non-small cell lung cancer. Lung Cancer 18(suppl 1):43, 1997. e-Pub 1997.
Lee JS, Komaki R, Fossella FV, Glisson BS, Cox JD, Hong WK. Long-term survival outcome of patients with inoperable NSCLC following concurrent chemoradiation therapy with oral etoposide and cisplatin. Lung Cancer 18(suppl 1):88, 1997. e-Pub 1997.
Fossella FV. Docetaxel for non-small cell lung cancer (slide presentation). Lung Cancer 18(suppl 2):62, 1997. e-Pub 1997.
Mendoza E, Fossella FV, Haskell C, Pisters K, Orlandi C, Dixon M, Figlin R. Adenosine triphosphate (ATP) for advanced non-small cell lung cancer: A phase II multicenter study. Proc ASCO 15:406, 1996. e-Pub 1996.
Fossella FV, Madden T, Wester M, Gorelick K, Murphy WK, Shin DM, Perez-Soler R, Lee JS, Rivera E, Kunz AY, Newman R. Phase I trial of GL331, a novel topoisomerase-II inhibitor, for advanced refractory cancer. Proc ASCO 15:492 (Poster presentation), 1996. e-Pub 1996.
Lee JS, Jung MC, Shin DM, Kurie JM, Heyne K, Wester M, Murphy WK, Perez-Soler R, Glisson BS, Fossella FV, Hong WK. Acceleration of cisplatin/etoposide chemotherapy by filgrastim in patients with non-small cell lung cancer. Proc ASCO 15:390, 1996. e-Pub 1996.
Fossella FV. Second-line chemotherapy in non-small cell lung cancer (slide presentation). Perspectives in Lung Cancer 37, 1996. e-Pub 1996.

Book Chapters

Fossella FV. Small Cell Lung Cancer. In: 60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center. First. Springer, 63-75, 2013.
Fossella FV. Chemotherapy in previously-treated NSCLC patients. In: Stewart D: Editor of Lung Cancer: Prevention, Management and Emerging Therapies. 3rd. Humana Press, 195-204, 2010.
Putnam JB, Fossella FV, Komaki R. Implementation of multidisciplinary care in the treatment of patients with lung cancer. In: M. D. Anderson Associates Monograph on Lung Cancer. Springer-Verlag, 1-24, 2003.
Fossella FV. Clinical evaluation of lung cancer. In: M. D. Anderson Associates Monograph on Lung Cancer. New York, 25-34, 2003.
Fossella F, Liao Z, Komaki R. Combinations of radiation therapy and chemotherapy for lung cancer. In: In: Roth JA, Hong WK, Cox JD: editors of Lung Cancer (3rd Edition). Third, 2003.
Fossella FV. Second-line Chemotherapy for Non-Small Cell Lung Cancer. In: Lung Cancer Updates, 2001.
Fossella FV. Chemotherapy for Non-Small Cell Lung Cancer: Second-Line Therapy. In: Lung Cancer. Lippincott Williams & Wilkins, 903-909, 2000.
Henke S, Fossella FV. Lung Cancer. In: Primary Care Oncology. WB Saunders Company, 57-76, 1999.
Fossella FV, Lee JS, Hong WK. Docetaxel in Chemotherapy Refractory or Recurrent Non-Small Cell Lung Cancer. In: Taxanes in Lung Cancer. Marcel Dekker, Inc, 127-139, 1998.

Books (edited and written)

Fossella FV, Komaki R, Putnam J. M. D. Anderson Associates Monograph on Lung Cancer. Springer-Verlag, 2003.
Fossella FV. Living Your Life with Lung Cancer, 2001.

Letters to the Editor

Rice D, Swisher S, Pister K, Fossella FV, Herbst R, Hofstetter W, Kies M, Komaki R, Lippman S, Mehran R, Roth J, Stewart D, Vaporciyan A, Walsh G, Cox J. Comment on: Treatment of non-small cell lung cancer stage IIIa: ACCP evidence-based clinical practice guidelines. Chest 3(Suppl): 243S-265S, 2007.

Less

CV information above last modified March 13, 2026

Frank V. Fossella, MD

About Dr. Frank V. Fossella

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Clinical Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Professional Educational Materials

Other Articles

Editorials

Abstracts

Book Chapters

Books (edited and written)

Letters to the Editor

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Frank V. Fossella, MD

About Dr. Frank V. Fossella

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Clinical Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Professional Educational Materials

Other Articles

Editorials

Abstracts

Book Chapters

Books (edited and written)

Letters to the Editor

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop UT MD Anderson